The University of Chicago Header Logo

Scott E. Eggener

TitleProfessor
InstitutionUniversity of Chicago
DepartmentSurgery-Urology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Eggener’s research and clinical interests focus on improving the management and outcomes for patients with localized prostate cancer with specific emphasis on active surveillance, focal therapy and optimizing surgical outcomes. He has published extensively on prostate cancer with 75 peer-reviewed publications and multiple on PSA screening, surgery, prostate imaging, active surveillance or focal therapy for prostate cancer. He is on the editorial board of four journals, including Prostate Cancer and Prostatic Diseases.

    Collapse Biography 
    Collapse education and training
    Memorial Sloan-Kettering Cancer Center, New YorkUrologic oncology fellowship
    Northwestern Memorial Hospital, ChicagoGeneral and urologic surgery internship and residency
    Standford University School of Medicine, CaliforniaMD

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Yu EY, Rumble RB, Agarwal N, Cheng HH, Eggener SE, Bitting RL, Beltran H, Giri VN, Spratt D, Mahal B, Lu K, Crispino T, Trabulsi EJ. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. J Clin Oncol. 2025 Jan 09; JCO2402608. PMID: 39787437.
      Citations:    Fields:    
    2. Chatterjee A, Yousuf AN, Engelmann R, Harmath C, Lee G, Medved M, Jamison EB, Lorente Campos A, Gundogdu B, Gerber G, Reynolds LF, Modi PK, Antic T, Giurcanu M, Eggener S, Karczmar GS, Oto A. Prospective Validation of an Automated Hybrid Multidimensional MRI Tool for Prostate Cancer Detection Using Targeted Biopsy: Comparison with PI-RADS-based Assessment. Radiol Imaging Cancer. 2025 Jan; 7(1):e240156. PMID: 39836080.
      Citations:    
    3. Ballas LK, Reddy CA, Han HR, Makar JB, Mian O, Broughman J, de Bustamante C, Eggener S, Liauw SL, Abramowitz M, Montoya C, Tendulkar R, Ballas LK, Reddy CA, Han HR, Makar JB, Mian O, Broughman J, de Bustamante C, Eggener S, Liauw SL, Abramowitz M, Montoya C, Tendulkar R. Patterns of Recurrence Following Radiation and ADT for Pathologic Lymph Node-Positive Prostate Cancer: A Multi-institutional Study. Pract Radiat Oncol. 2024 Dec 27. PMID: 39733964.
      Citations:    Fields:    
    4. Antonelli L, Heidenreich A, Bagrodia A, Amini A, Baky F, Branger N, Cazzaniga W, Clinton TN, Daneshmand S, Djaladat H, Eggener S, Ghoreifi A, Hamilton RJ, Ho M, Sexton WJ, Nazzani S, Nicol D, Nicolai N, Olson K, Paffenholz P, Porter J, Qian Z, Rocco NR, Yerrapragada A, Stroup SP, Tachibana I, Terbuch A, Singla N, Cary C, Fankhauser CD, EAU-YAU Penile and Testis Cancer Working Group. Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumour. BJU Int. 2024 Dec 11. PMID: 39662898.
      Citations:    Fields:    
    5. Eggener S, Liauw SL. Genomic Classifiers To Guide Postprostatectomy Radiation Therapy: An Opening Movement in G-MINOR. Eur Urol. 2024 Nov 29. PMID: 39616001.
      Citations:    Fields:    
    6. Zhao Y, Gulati R, Yang Z, Newcomb L, Zheng Y, Zhu K, Liu M, Heijnsdijk EAM, Haffner MC, Cooperberg M, Eggener SE, De Marzo AM, Kibel AS, Rizopoulos D, Hall IJ, Etzioni R. Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling. J Natl Cancer Inst. 2024 Nov 20. PMID: 39565901.
      Citations:    Fields:    
    7. Ghoreifi A, Sheybaee Moghaddam F, Mitra AP, Khanna A, Singh A, Chavarriaga J, Moon SC, Goolam AS, Chuang R, Rich JM, Baky FJ, Ho M, Roberts J, Gill IS, Porter JR, Ahmadi N, Mehrazin R, Sfakianos JP, Rais-Bahrami S, Bagrodia A, Hamilton RJ, Eggener S, Rawal S, Ward JF, Djaladat H. Oncological Outcomes Following Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer: A Worldwide Multicenter Study. Eur Urol Focus. 2024 Nov 16. PMID: 39551650.
      Citations:    Fields:    
    8. Huang D, Lynch C, Serra LM, Sweis RF, Chang PJ, Stadler WM, Szmulewitz RZ, O'Donnell PH, Sidana A, Eggener SE, Shalhav AL, Liauw SL, Pitroda SP. Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma. Clin Transl Radiat Oncol. 2024 Nov; 49:100879. PMID: 39529961; PMCID: PMC11551534.
      Citations:    
    9. Chatterjee A, Fan X, Slear J, Asare G, Yousuf AN, Medved M, Antic T, Eggener S, Karczmar GS, Oto A. Quantitative Multi-Parametric MRI of the Prostate Reveals Racial Differences. Cancers (Basel). 2024 Oct 16; 16(20). PMID: 39456593; PMCID: PMC11505680.
      Citations:    
    10. Lazarovich A, Kristof TW, Steadman S, Dahmen AS, Josephson MA, Barth R, Morgan TM, Timsit MO, Eggener S. Prostate cancer and solid organ transplantation: patient management and outcomes. BJU Int. 2025 Feb; 135(2):339-345. PMID: 39385314; PMCID: PMC11745990.
      Citations:    Fields:    
    11. Cooperberg MR, Braun AE, Berlin A, Kibel AS, Eggener SE, CANCER-GG1 Writing Group . When is prostate cancer really cancer? J Natl Cancer Inst. 2024 Oct 01. PMID: 39350309.
      Citations:    Fields:    
    12. Hoffmann TJ, Graff RE, Madduri RK, Rodriguez AA, Cario CL, Feng K, Jiang Y, Wang A, Klein RJ, Pierce BL, Eggener S, Tong L, Blot W, Long J, Rebbeck T, Lachance J, Andrews C, Adebiyi AO, Adusei B, Aisuodionoe-Shadrach OI, Fernandez PW, Jalloh M, Janivara R, Chen WC, Mensah JE, Agalliu I, Berndt SI, Shelley JP, Schaffer K, Machiela MJ, Freedman ND, Huang WY, Li SA, Goodman PJ, Till C, Thompson I, Lilja H, Van Den Eeden SK, Chanock SJ, Mosley JD, Conti DV, Haiman CA, Justice AC, Kachuri L, Witte JS, Graff RE, Cario CL, Klein RJ, Goss LB, Darst BF, Lachance J, Machiela MJ, Ranatunga DK, Presti J, Mosley JD, Kachuri L. Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves cross-ancestry prediction. medRxiv. 2024 Aug 20. PMID: 37961155; PMCID: PMC10635224.
      Citations:    
    13. Vigneswaran HT, Eklund M, Discacciati A, Nordström T, Hubbard RA, Perlis N, Abern MR, Moreira DM, Eggener S, Yonover P, Chow AK, Watts K, Liss MA, Thoreson GR, Abreu AL, Sonn GA, Palsdottir T, Plym A, Wiklund F, Grönberg H, Murphy AB, SEPTA STHLM3 Study Group. Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial. J Clin Oncol. 2024 Nov 10; 42(32):3806-3816. PMID: 39038251.
      Citations: 3     Fields:    Translation:Humans
    14. Fankhauser CD, Eggener S. Overcoming the Code Duello: Achieving Long-term Cure and Optimizing Quality of Life in Testicular Cancer. Eur Urol Focus. 2024 May; 10(3):355-356. PMID: 39013684.
      Citations:    Fields:    Translation:Humans
    15. Rezaee ME, Elias R, Li HL, Agrawal P, Pallauf M, Enikeev D, Ged Y, Eggener S, Singla N. Survival outcomes and molecular drivers of testicular cancer in hispanic men. Urol Oncol. 2024 Sep; 42(9):293.e1-293.e7. PMID: 38821727.
      Citations:    Fields:    Translation:Humans
    16. Watt KD, Rolak S, Foley DP, Plichta JK, Pruthi S, Farr D, Zwald FO, Carvajal RD, Dudek AZ, Sanger CB, Rocco R, Chang GJ, Dizon DS, Langstraat CL, Teoh D, Agarwal PK, Al-Qaoud T, Eggener S, Kennedy CC, D'Cunha J, Mohindra NA, Stewart S, Habermann TH, Schuster S, Lunning M, Shah NN, Gertz MA, Mehta J, Suvannasankha A, Verna E, Farr M, Blosser CD, Hammel L, Al-Adra DP. Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion. Transplantation. 2024 May 21. PMID: 38771067.
      Citations:    Fields:    
    17. Rajeev-Kumar G, Pitroda SP, Szmulewitz RZ, Skolarus T, Eggener SE, Liauw SL. Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an Alternative to Gonadotropin Releasing Hormone Agonists. Clin Genitourin Cancer. 2024 Aug; 22(4):102103. PMID: 38781786.
      Citations:    Fields:    Translation:Humans
    18. Crawford ED, Bryce AH, Hussain MH, Agarwal N, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1. JU Open Plus. 2024 Apr; 2(4). PMID: 38774466; PMCID: PMC11108024.
      Citations: 1     
    19. Bryce AH, Crawford ED, Agarwal N, Hussain MH, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. JU Open Plus. 2024 Apr; 2(4). PMID: 38774467; PMCID: PMC11107999.
      Citations: 1     
    20. Villota CK, Hou SW, Judge C, Eggener S, Paner G, Raheem OA. Ex-vivo microscopic oncotesticular sperm extraction: step-by-step surgical technique at time of radical orchiectomy. Fertil Steril. 2024 Jun; 121(6):1069-1071. PMID: 38403108.
      Citations:    Fields:    Translation:Humans
    21. Vickers AJ, Assel M, Cooperberg MR, Fine SW, Eggener S. Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer. Eur Urol. 2024 Jul; 86(1):1-3. PMID: 38278665.
      Citations:    Fields:    Translation:Humans
    22. Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ, EORTC-55994 Study Group. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 01; 42(10):1114-1123. PMID: 38261983; PMCID: PMC11637124.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    23. Yeo KJ, Ho MD, Eggener SE. Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen. Am J Clin Pathol. 2024 Jan 04; 161(1):1-3. PMID: 37639675.
      Citations:    Fields:    Translation:Humans
    24. Li J, Paner GP, Berlin A, Ramotar M, Santiago AT, Liu Z, Wolinsky H, Wallis CJD, Chua MLK, van der Kwast T, Cooperberg MR, Vickers AJ, Urbach DR, Eggener SE. The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer. J Natl Cancer Inst. 2023 11 08; 115(11):1364-1373. PMID: 37285311; PMCID: PMC10637044.
      Citations: 3     Fields:    Translation:Humans
    25. Antonelli L, Ardizzone D, Tachibana I, Adra N, Cary C, Hugar L, Sexton WJ, Bagrodia A, Mego M, Daneshmand S, Nicolai N, Nazzani S, Giannatempo P, Franza A, Heidenreich A, Paffenholz P, Saoud R, Eggener S, Ho M, Oswald N, Olson K, Tryakin A, Fedyanin M, Naoun N, Javaud C, Cazzaniga W, Nicol D, Gerdtsson A, Tandstad T, Fizazi K, Fankhauser CD, EAU-YAU Penile and Testis Cancer Working Group. Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. J Clin Oncol. 2023 Dec 01; 41(34):5296-5305. PMID: 37656935.
      Citations: 2     Fields:    Translation:Humans
    26. Yim K, Ma C, Penney K, Kibel AS, Eggener S, Preston MA, Carlsson S, Mucci L, Lilja H. Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial. J Urol. 2023 10; 210(4):630-638. PMID: 37384841; PMCID: PMC10894656.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    27. Lee G, Chatterjee A, Harmath C, Karademir I, Engelmann R, Yousuf A, Islam S, Karczmar G, Oto A, Giurcanu M, Antic T, Eggener S. Improving reader accuracy and specificity with the addition of hybrid multidimensional-MRI to multiparametric-MRI in diagnosing clinically significant prostate cancers. Abdom Radiol (NY). 2023 10; 48(10):3216-3228. PMID: 37358605.
      Citations: 1     Fields:    Translation:Humans
    28. Saoud R, Woranisarakul V, Paner GP, Ramotar M, Berlin A, Cooperberg M, Eggener SE. Physician Perception of Grade Group 1 Prostate Cancer. Eur Urol Focus. 2023 11; 9(6):966-973. PMID: 37117112.
      Citations:    Fields:    Translation:Humans
    29. Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, Fine SW, Han M, Kim SK, Kirkby E, Miner M, Moses K, Pinto PA, Salami SS, Lin DW, Konety BR, Nissenberg MG, Souter L, Thompson IM. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. J Urol. 2023 07; 210(1):54-63. PMID: 37096575; PMCID: PMC11321723.
      Citations: 31     Fields:    Translation:Humans
    30. Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, Fine SW, Han M, Kim SK, Kirkby E, Miner M, Moses K, Pinto PA, Salami SS, Lin DW, Konety BR, Nissenberg MG, Souter L, Thompson IM. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. J Urol. 2023 07; 210(1):46-53. PMID: 37096582; PMCID: PMC11060750.
      Citations: 52     Fields:    Translation:HumansPHPublic Health
    31. Paner GP, Zhou M, Simko JP, Eggener SE, van der Kwast T. Renaming Grade Group 1 Prostate "Cancer" From a Pathology Perspective: A Call for Multidisciplinary Discussion. Adv Anat Pathol. 2023 Apr 17. PMID: 37072903.
      Citations: 1     Fields:    
    32. Ho MD, Ross AE, Eggener SE. Risk Stratification of Low-risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance. J Urol. 2023 07; 210(1):38-45. PMID: 37042807.
      Citations: 5     Fields:    Translation:Humans
    33. Vickers A, Berlin A, Paner G, Cooperberg M, Wolinsky H, Eggener S. Reply to X. Farré et al. JCO Glob Oncol. 2023 Apr; 9:e2300015. PMID: 37099737; PMCID: PMC10281445.
      Citations:    Fields:    
    34. Daneshmand S, Cary C, Masterson T, Einhorn L, Adra N, Boorjian SA, Kollmannsberger C, Schuckman A, So A, Black P, Bagrodia A, Skinner E, Alemozaffar M, Brand T, Eggener S, Pierorazio P, Stratton K, Nappi L, Nichols C, Luo C, Li M, Hu B. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. J Clin Oncol. 2023 06 01; 41(16):3009-3018. PMID: 36913642.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    35. Antonelli L, Ardizzone D, Ravi P, Bagrodia A, Mego M, Daneshmand S, Nicolai N, Nazzani S, Giannatempo P, Franza A, Heidenreich A, Paffenholz P, Saoud R, Eggener S, Ho M, Oswald N, Olson K, Tryakin A, Fedyanin M, Naoun N, Javaud C, Fizazi K, King JM, Adra N, Douglawi A, Cary C, Sweeney C, Fankhauser CD. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study. Eur J Cancer. 2023 03; 182:144-154. PMID: 36787661.
      Citations: 1     Fields:    Translation:Humans
    36. Eggener SE, Berlin A, Vickers AJ, Paner GP, Wolinsky H, Cooperberg MR. Reply to M. Baboudjian et al. J Clin Oncol. 2023 Mar 01; 41(7):1493-1494. PMID: 36459669.
      Citations:    Fields:    
    37. Ghoreifi A, Mitra AP, McClintock G, Baky F, McDowell Z, Saoud R, Cai J, Gill IS, Sfakianos J, Porter J, Bagrodia A, Ahmadi N, Eggener S, Ward JF, Djaladat H, Lavallée E. Robotic post-chemotherapy retroperitoneal lymph node dissection for testicular cancer: A multicenter collaborative study. Urol Oncol. 2023 02; 41(2):111.e7-111.e14. PMID: 36437156.
      Citations: 3     Fields:    Translation:Humans
    38. Witmer HDD, Dhiman A, Giurcanu M, Eng OS, Eggener S, Kindler HL, Turaga KK. A population-based evaluation of tunica vaginalis mesothelioma: An analysis of the National Cancer Database. Urol Oncol. 2023 01; 41(1):52.e11-52.e20. PMID: 36319552.
      Citations:    Fields:    Translation:Humans
    39. Vickers AJ, Cooperberg MR, Eggener SE. Removing the Designation of Cancer from Grade Group 1 Disease Will Do More Good than Harm. Eur Urol. 2023 04; 83(4):304-306. PMID: 36280498.
      Citations: 1     Fields:    Translation:Humans
    40. Labbate CV, Klotz L, Morrow M, Cooperberg M, Esserman L, Eggener SE. Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment. J Urol. 2023 01; 209(1):49-57. PMID: 36129376.
      Citations: 4     Fields:    Translation:Humans
    41. Andolfi C, Vickers AJ, Cooperberg MR, Carroll PR, Cowan JE, Paner GP, Helfand BT, Liauw SL, Eggener SE. Blood Prostate-specific Antigen by Volume of Benign, Gleason Pattern 3 and 4 Prostate Tissue. Urology. 2022 12; 170:154-160. PMID: 35987380; PMCID: PMC10515713.
      Citations: 3     Fields:    Translation:Humans
    42. Meza J, Babajide R, Saoud R, Sweis J, Abelleira J, Helenowski I, Jovanovic B, Eggener S, Miller FH, Horowitz JM, Casalino DD, Murphy AB. Assessing the accuracy of multiparametric MRI to predict clinically significant prostate cancer in biopsy naïve men across racial/ethnic groups. BMC Urol. 2022 Jul 18; 22(1):107. PMID: 35850677; PMCID: PMC9295380.
      Citations: 1     Fields:    Translation:Humans
    43. Gupta N, Patel HD, Taylor J, Borin JF, Jacobsohn K, Kenfield SA, Eggener SE, Price C, Davuluri M, Byrne N, Bivalacqua TJ, Loeb S. Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes. Prostate Cancer Prostatic Dis. 2022 09; 25(3):444-452. PMID: 35790788.
      Citations: 9     Fields:    Translation:Humans
    44. Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, Eggener S, Horwitz EM, Kane CJ, Kirkby E, Lin DW, McBride SM, Morgans AK, Pierorazio PM, Rodrigues G, Wong WW, Boorjian SA. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions. J Urol. 2022 07; 208(1):26-33. PMID: 35536141.
      Citations: 20     Fields:    Translation:Humans
    45. Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, Eggener S, Horwitz EM, Kane CJ, Kirkby E, Lin DW, McBride SM, Morgans AK, Pierorazio PM, Rodrigues G, Wong WW, Boorjian SA. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol. 2022 07; 208(1):10-18. PMID: 35536144.
      Citations: 92     Fields:    Translation:Humans
    46. Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, Eggener S, Horwitz EM, Kane CJ, Kirkby E, Lin DW, McBride SM, Morgans AK, Pierorazio PM, Rodrigues G, Wong WW, Boorjian SA. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up. J Urol. 2022 07; 208(1):19-25. PMID: 35536148.
      Citations: 55     Fields:    Translation:Humans
    47. Eggener SE, Berlin A, Vickers AJ, Paner GP, Wolinsky H, Cooperberg MR. Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. J Clin Oncol. 2022 09 20; 40(27):3110-3114. PMID: 35436144.
      Citations: 20     Fields:    Translation:Humans
    48. Nyame YA, Cooperberg MR, Cumberbatch MG, Eggener SE, Etzioni R, Gomez SL, Haiman C, Huang F, Lee CT, Litwin MS, Lyratzopoulos G, Mohler JL, Murphy AB, Pettaway C, Powell IJ, Sasieni P, Schaeffer EM, Shariat SF, Gore JL. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol. 2022 10; 82(4):341-351. PMID: 35367082.
      Citations: 25     Fields:    Translation:Humans
    49. Modi PK, Eggener SE. Radical Prostatectomy Without Biopsy: Audacious, Imprudent, or Innovative? Eur Urol. 2022 08; 82(2):161-162. PMID: 35346513.
      Citations:    Fields:    Translation:Humans
    50. Fankhauser CD, Afferi L, Stroup SP, Rocco NR, Olson K, Bagrodia A, Baky F, Cazzaniga W, Mayer E, Nicol D, Islamoglu E, de Vergie S, Saoud R, Eggener SE, Nazzani S, Nicolai N, Hugar L, Sexton WJ, Matei DV, De Cobelli O, Cheaib J, Pierorazio PM, Porter J, Hermanns T, Hamilton RJ, Hiester A, Albers P, Clarke N, Mattei A. Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World J Urol. 2022 Jun; 40(6):1505-1512. PMID: 35279732.
      Citations: 6     Fields:    Translation:Humans
    51. Turchan WT, Cutright D, Wu T, Leng JX, Dignam JJ, Eggener SE, Liauw SL. Reply by Authors. J Urol. 2022 06; 207(6):1245. PMID: 35236091.
      Citations:    Fields:    
    52. Eggener S, Siemens DR. Prostate Cancer, Decisional Regret and Exercise. J Urol. 2022 05; 207(5):952-953. PMID: 35080461.
      Citations:    Fields:    Translation:Humans
    53. Turchan WT, Cutright D, Wu T, Leng JX, Dignam JJ, Eggener SE, Liauw SL. Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup. J Urol. 2022 06; 207(6):1236-1245. PMID: 35050703.
      Citations: 2     Fields:    Translation:Humans
    54. Eggener S. Editorial Comment. J Urol. 2022 05; 207(5):1066. PMID: 35042391.
      Citations:    Fields:    
    55. Grummet J, Eggener S. Re: NCCN Prostate Cancer Guidelines Version 1.2022 - September 10, 2021. Eur Urol. 2022 02; 81(2):218. PMID: 34895925.
      Citations: 3     Fields:    Translation:Humans
    56. Saoud R, Kristof TW, Judge C, Chumbalkar V, Antic T, Eggener S, Modi P. Clinical and pathological features of renal epithelioid angiomyolipoma (PEComa): A single institution series. Urol Oncol. 2022 02; 40(2):18-24. PMID: 34815169.
      Citations: 7     Fields:    Translation:Humans
    57. Cooperberg MR, Lin DW, Morgan TM, Chapin BF, Chen RC, Eggener SE. Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. J Urol. 2022 02; 207(2):262-264. PMID: 34775795.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    58. Chatterjee A, Mercado C, Bourne RM, Yousuf A, Hess B, Antic T, Eggener S, Oto A, Karczmar GS. Validation of Prostate Tissue Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic Findings. Radiology. 2022 02; 302(2):368-377. PMID: 34751615; PMCID: PMC8805656.
      Citations: 14     Fields:    Translation:Humans
    59. Turchan WT, Cutright D, Wu T, Leng JX, Eggener S, Liauw S. Incidence and Severity of Hematuria After Post-Prostatectomy Radiotherapy in a Cohort With Long-Term Follow-up. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):e296. PMID: 34701117.
      Citations:    
    60. Tatjana A, Tjota MY, O'Donnell PH, Eggener SE, Agarwal PK, Haridas R, Segal J, Wang P. EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma. Virchows Arch. 2022 Feb; 480(2):487-492. PMID: 34128116.
      Citations: 2     Fields:    Translation:Humans
    61. Eggener SE. Editorial Comment. J Urol. 2021 09; 206(3):668. PMID: 34074115.
      Citations:    Fields:    
    62. Asghar AM, McIntosh AG, Smith ZL, Kocher NJ, Lee Z, Barashi NN, Li T, Raman JD, Eggener SE, Uzzo RG, Kutikov A. Pathological characteristics of the large renal mass: potential implication for clinical role of renal biopsy. Can J Urol. 2021 04; 28(2):10620-10624. PMID: 33872561.
      Citations: 1     Fields:    Translation:Humans
    63. Vickers AJ, Russo G, Lilja H, Evans C, Schalken JA, Klein E, Eggener S. How Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer? Eur Urol Oncol. 2022 04; 5(2):135-137. PMID: 33608234.
      Citations: 8     Fields:    Translation:Humans
    64. Labbate CV, Paner GP, Eggener SE. Should Grade Group 1 (GG1) be called cancer? World J Urol. 2022 Jan; 40(1):15-19. PMID: 33432506.
      Citations: 6     Fields:    Translation:Humans
    65. Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Serrallach M, Relle J, Lotan Y, Heidenreich A, Bonekamp D, Haider M, Tirkes T, Arora S, Macura KJ, Costa DN, Persigehl T, Pantuck AJ, Bomers J, Burtnyk M, Staruch R, Eggener S, Fütterer J. Reply by Authors. J Urol. 2021 03; 205(3):779. PMID: 33355501.
      Citations: 1     Fields:    
    66. Eggener SE, Agarwal PK. Re: Pretransplant Solid Organ Malignancy and Organ Transplant Candidacy: A Consensus Expert Opinion Statement. Eur Urol. 2021 04; 79(4):552-553. PMID: 33303242.
      Citations:    Fields:    Translation:Humans
    67. Shi Z, Platz EA, Wei J, Na R, Fantus RJ, Wang CH, Eggener SE, Hulick PJ, Duggan D, Zheng SL, Cooney KA, Isaacs WB, Helfand BT, Xu J. Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. Eur Urol. 2021 03; 79(3):419-426. PMID: 33257031.
      Citations: 17     Fields:    Translation:Humans
    68. Ali W, Nathan S, Funaki B, Eggener S, Bakris G. An Unusual Case of Resistant Hypertension Secondary to Fibromuscular Dysplasia. JACC Case Rep. 2020 Dec; 2(15):2460-2464. PMID: 34317194; PMCID: PMC8304536.
      Citations:    
    69. Saoud RM, Andolfi C, Aizen J, Wymer K, Burg M, Barashi N, Daneshmand S, Eggener S. Impact of Non-guideline-directed Care on Quality of Life in Testicular Cancer Survivors. Eur Urol Focus. 2021 Sep; 7(5):1137-1142. PMID: 33121935.
      Citations: 6     Fields:    Translation:Humans
    70. Al-Adra DP, Hammel L, Roberts J, Woodle ES, Levine D, Mandelbrot D, Verna E, Locke J, D'Cunha J, Farr M, Sawinski D, Agarwal PK, Plichta J, Pruthi S, Farr D, Carvajal R, Walker J, Zwald F, Habermann T, Gertz M, Bierman P, Dizon DS, Langstraat C, Al-Qaoud T, Eggener S, Richgels JP, Chang GJ, Geltzeiler C, Sapisochin G, Ricciardi R, Krupnick AS, Kennedy C, Mohindra N, Foley DP, Watt KD. Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. Am J Transplant. 2021 02; 21(2):460-474. PMID: 32969590; PMCID: PMC8576374.
      Citations: 32     Fields:    Translation:Humans
    71. Al-Adra DP, Hammel L, Roberts J, Woodle ES, Levine D, Mandelbrot D, Verna E, Locke J, D'Cunha J, Farr M, Sawinski D, Agarwal PK, Plichta J, Pruthi S, Farr D, Carvajal R, Walker J, Zwald F, Habermann T, Gertz M, Bierman P, Dizon DS, Langstraat C, Al-Qaoud T, Eggener S, Richgels JP, Chang GJ, Geltzeiler C, Sapisochin G, Ricciardi R, Krupnick AS, Kennedy C, Mohindra N, Foley DP, Watt KD. Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. Am J Transplant. 2021 02; 21(2):475-483. PMID: 32976703; PMCID: PMC8555431.
      Citations: 25     Fields:    Translation:Humans
    72. Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Serrallach M, Relle J, Lotan Y, Heidenreich A, Bonekamp D, Haider M, Tirkes T, Arora S, Macura KJ, Costa DN, Persigehl T, Pantuck AJ, Bomers J, Burtnyk M, Staruch R, Eggener S, Fütterer J. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. J Urol. 2021 Mar; 205(3):769-779. PMID: 33021440.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    73. Sun C, Wang S, Chatterjee A, Medved M, Eggener S, Karczmar GS, Oto A. T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy. Eur Radiol. 2021 Jan; 31(1):325-332. PMID: 32785769; PMCID: PMC7755698.
      Citations: 1     Fields:    Translation:Humans
    74. Press DJ, Pierce B, Lauderdale DS, Aschebrook-Kilfoy B, Lin Gomez S, Hedeker D, Wright NE, Fantus RJ, Ahsan H, Eggener S, Bettencourt L. Tobacco and marijuana use and their association with serum prostate-specific antigen levels among African American men in Chicago. Prev Med Rep. 2020 Dec; 20:101174. PMID: 33088675; PMCID: PMC7566952.
      Citations: 3     
    75. Liauw SL, Ham SA, Das LC, Rudra S, Packiam VT, Koshy M, Weichselbaum RR, Becker YT, Bodzin AS, Eggener SE. Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. J Natl Cancer Inst. 2020 08 01; 112(8):847-854. PMID: 31728517; PMCID: PMC8453608.
      Citations: 13     Fields:    Translation:Humans
    76. Modi PK, Eggener SE. Prostate-specific Antigen to Predict Early Success of Focal Therapy: Focusing on Appropriate Endpoints. Eur Urol. 2020 08; 78(2):161-162. PMID: 32593531.
      Citations:    Fields:    Translation:Humans
    77. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 08 20; 38(24):2798-2811. PMID: 32516092; PMCID: PMC7430215.
      Citations: 104     Fields:    Translation:Humans
    78. Eggener S. Editorial Comment. J Urol. 2020 08; 204(2):287. PMID: 32432506.
      Citations:    Fields:    Translation:Humans
    79. Labbate CV, Werntz RP, Galansky LB, Packiam VT, Eggener SE. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy. Urol Oncol. 2020 08; 38(8):687.e13-687.e18. PMID: 32305267.
      Citations: 1     Fields:    Translation:Humans
    80. Eggener SE, Rumble RB, Beltran H. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline Summary. JCO Oncol Pract. 2020 06; 16(6):340-343. PMID: 32048932.
      Citations: 6     Fields:    Translation:Humans
    81. Werntz RP, Eggener SE. Defining risk of micrometastatic disease and tumor recurrence in patients with stage I testicular germ cell tumors. Transl Androl Urol. 2020 Jan; 9(Suppl 1):S31-S35. PMID: 32055483; PMCID: PMC6995846.
      Citations: 2     
    82. Eggener SE, Rumble RB, Armstrong AJ, Morgan TM, Crispino T, Cornford P, van der Kwast T, Grignon DJ, Rai AJ, Agarwal N, Klein EA, Den RB, Beltran H. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020 05 01; 38(13):1474-1494. PMID: 31829902.
      Citations: 64     Fields:    Translation:Humans
    83. Eggener SE. Recognizing and minimizing bias: Helping patients make their best choice for prostate cancer management through multidisciplinary clinics. Cancer. 2020 02 01; 126(3):470-472. PMID: 31742661.
      Citations: 1     Fields:    Translation:Humans
    84. Bjurlin MA, Carroll PR, Eggener S, Fulgham PF, Margolis DJ, Pinto PA, Rosenkrantz AB, Rubenstein JN, Rukstalis DB, Taneja SS, Turkbey B. Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2020 Apr; 203(4):706-712. PMID: 31642740; PMCID: PMC8274953.
      Citations: 86     Fields:    Translation:HumansPHPublic Health
    85. Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC. SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. J Urol. 2019 11; 202(5):952-958. PMID: 31144591.
      Citations: 4     Fields:    Translation:Humans
    86. Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC. Reply by Authors. J Urol. 2019 11; 202(5):958. PMID: 31364932.
      Citations:    Fields:    Translation:Humans
    87. Eggener S. Editorial Comment. J Urol. 2019 11; 202(5):942-943. PMID: 31364943.
      Citations:    Fields:    Translation:Humans
    88. Porter J, Eggener S, Castle E, Pierorazio P. Recurrence After Robotic Retroperitoneal Lymph Node Dissection Raises More Questions than Answers. Eur Urol. 2019 11; 76(5):610-611. PMID: 31543365.
      Citations: 3     Fields:    Translation:Humans
    89. Weinstock C, Suzman D, Kluetz P, Baxley J, Viviano C, Ibrahim A, Jarow J, Sridhara R, Liu K, Carroll P, Eggener S, Hu JC, Hussain M, King M, Klein E, Kungel T, Makarov D, Pinto PA, Rini B, Roach M, Sandler H, Schlegel PN, Song D, Goldberg K, Pazdur R, Beaver JA. Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop. J Urol. 2020 01; 203(1):115-119. PMID: 31502940; PMCID: PMC8274949.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    90. Baack Kukreja J, Bathala TK, Reichard CA, Troncoso P, Delacroix S, Davies B, Eggener S, Smaldone M, Minhaj Siddiqui M, Tollefson M, Chapin BF. Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2020 03; 23(1):172-178. PMID: 31501508; PMCID: PMC7027969.
      Citations: 6     Fields:    Translation:Humans
    91. Stephenson A, Eggener SE, Bass EB, Chelnick DM, Daneshmand S, Feldman D, Gilligan T, Karam JA, Leibovich B, Liauw SL, Masterson TA, Meeks JJ, Pierorazio PM, Sharma R, Sheinfeld J. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. J Urol. 2019 08; 202(2):272-281. PMID: 31059667.
      Citations: 73     Fields:    Translation:Humans
    92. Eggener S. Editorial Comment. J Urol. 2019 08; 202(2):263. PMID: 31067164.
      Citations:    Fields:    Translation:Humans
    93. Ghandour R, Ashbrook C, Freifeld Y, Singla N, El-Asmar JM, Lotan Y, Margulis V, Eggener S, Woldu S, Bagrodia A. Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. Eur Urol Oncol. 2020 04; 3(2):198-206. PMID: 31272940.
      Citations: 3     Fields:    Translation:Humans
    94. Bhanvadia RR, Rodriguez J, Bagrodia A, Eggener SE. Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis. BJU Int. 2019 11; 124(5):792-800. PMID: 31054211.
      Citations: 8     Fields:    Translation:Humans
    95. Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF. The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. Eur Urol. 2019 Sep; 76(3):268-272. PMID: 31128968.
      Citations: 15     Fields:    Translation:Humans
    96. Akthar AS, Liao C, Eggener SE, Liauw SL. Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy. Eur Urol. 2019 11; 76(5):686-692. PMID: 31113644.
      Citations: 10     Fields:    Translation:HumansPHPublic Health
    97. Pinsky PF, Black A, Daugherty SE, Hoover R, Parnes H, Smith ZL, Eggener S, Andriole GL, Berndt SI. Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer. 2019 09 01; 125(17):2965-2974. PMID: 31067347; PMCID: PMC6690759.
      Citations: 5     Fields:    Translation:Humans
    98. Chatterjee A, He D, Fan X, Antic T, Jiang Y, Eggener S, Karczmar GS, Oto A. Diagnosis of Prostate Cancer by Use of MRI-Derived Quantitative Risk Maps: A Feasibility Study. AJR Am J Roentgenol. 2019 08; 213(2):W66-W75. PMID: 31039019.
      Citations: 11     Fields:    Translation:Humans
    99. Osterberg EC, Golan S, Pes MPL, Eggener SE, Petrut B, Singh SK, Sountoulides P, Wolf JS, Türkeri LN. International and Multi-institutional Assessment of Factors Associated With Performance and Quality of Lymph Node Dissection During Radical Nephrectomy. Urology. 2019 Jul; 129:132-138. PMID: 31009740.
      Citations:    Fields:    Translation:Humans
    100. Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695. PMID: 30968729; PMCID: PMC6595543.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    101. Werntz RP, Eggener SE. Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015. Eur Urol. 2019 08; 76(2):252. PMID: 30962042.
      Citations:    Fields:    Translation:Humans
    102. Labbate C, Hatogai K, Werntz R, Stadler WM, Steinberg GD, Eggener S, Sweis RF. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J Immunother Cancer. 2019 03 11; 7(1):66. PMID: 30857555; PMCID: PMC6413449.
      Citations: 41     Fields:    Translation:Humans
    103. Eggener S. Editorial Comment. J Urol. 2019 02; 201(2):266-267. PMID: 30634353.
      Citations:    Fields:    Translation:Humans
    104. van Luijtelaar A, Greenwood BM, Ahmed HU, Barqawi AB, Barret E, Bomers JGR, Brausi MA, Choyke PL, Cooperberg MR, Eggener S, Feller JF, George AK, Hindley RG, Jenniskens SFM, Klotz L, Lindner U, Loeb S, Margolis DJ, Marks LS, May S, Mcclure TD, Montironi R, Nour SG, Oto A, Polascik TJ, Rastinehad AR, De Reyke TM, de la Rosette JJMCH, Sedelaar JPM, Sperling DS, Walser EM, Ward JF, Villers A, Ghai S, Frauscher F, Kovacs G, Reijnen JS, Fütterer JJ. Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. World J Urol. 2019 Oct; 37(10):2147-2153. PMID: 30671638; PMCID: PMC6763411.
      Citations: 15     Fields:    Translation:Humans
    105. Truong M, Baack Kukreja JE, Rais-Bahrami S, Barashi NS, Wang B, Nuffer Z, Park JH, Lam K, Frye TP, Nix JW, Thomas JV, Feng C, Chapin BF, Davis JW, Hollenberg G, Oto A, Eggener SE, Joseph JV, Weinberg E, Messing EM. Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging. Eur Urol Oncol. 2019 05; 2(3):257-264. PMID: 31200839.
      Citations: 2     Fields:    Translation:Humans
    106. Eggener S, Karsh LI, Richardson T, Shindel AW, Lu R, Rosenberg S, Goldfischer E, Korman H, Bennett J, Newmark J, Denes BS. A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility. Urology. 2019 04; 126:76-82. PMID: 30611659.
      Citations: 18     Fields:    Translation:Humans
    107. Pierorazio P, Eggener S. Obscenity, Michael Jordan, and Measuring Outcomes: Explaining and Improving the Quality of Kidney Cancer Care. Eur Urol. 2019 04; 75(4):635-636. PMID: 30578120.
      Citations:    Fields:    Translation:Humans
    108. Sun C, Chatterjee A, Yousuf A, Antic T, Eggener S, Karczmar GS, Oto A. Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology. AJR Am J Roentgenol. 2019 02; 212(2):351-356. PMID: 30540213.
      Citations: 34     Fields:    Translation:Humans
    109. Knull E, Oto A, Eggener S, Tessier D, Guneyli S, Chatterjee A, Fenster A. Evaluation of tumor coverage after MR-guided prostate focal laser ablation therapy. Med Phys. 2019 Feb; 46(2):800-810. PMID: 30447155.
      Citations: 2     Fields:    Translation:Humans
    110. Browne JA, Leir SH, Eggener SE, Harris A. Region-specific microRNA signatures in the human epididymis. Asian J Androl. 2018 Nov-Dec; 20(6):539-544. PMID: 30058558; PMCID: PMC6219309.
      Citations: 7     Fields:    Translation:HumansCells
    111. Wang S, Fan X, Yousuf A, Eggener SE, Karczmar G, Oto A. Evaluation of Focal Laser Ablation of Prostate Cancer Using High Spectral and Spatial Resolution Imaging: A Pilot Study. J Magn Reson Imaging. 2019 05; 49(5):1374-1380. PMID: 30291653.
      Citations: 1     Fields:    Translation:Humans
    112. He D, Chatterjee A, Fan X, Wang S, Eggener S, Yousuf A, Antic T, Oto A, Karczmar GS. Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium: Comparative Performance With Standard Dose in Prostate Cancer Diagnosis. Invest Radiol. 2018 10; 53(10):609-615. PMID: 29702525; PMCID: PMC6512866.
      Citations: 7     Fields:    Translation:Humans
    113. Weiner AB, Schaeffer EM, Eggener SE. "Real-world" Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer. Eur Urol. 2018 12; 74(6):708-709. PMID: 30224197.
      Citations:    Fields:    Translation:Humans
    114. Werntz RP, Pearce SM, Eggener SE. Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissection. Curr Opin Urol. 2018 09; 28(5):461-468. PMID: 29979235.
      Citations: 4     Fields:    Translation:Humans
    115. Yang R, Browne JA, Eggener SE, Leir SH, Harris A. A novel transcriptional network for the androgen receptor in human epididymis epithelial cells. Mol Hum Reprod. 2018 09 01; 24(9):433-443. PMID: 30016502; PMCID: PMC6454485.
      Citations: 9     Fields:    Translation:HumansCells
    116. Johnson SC, Smith ZL, Nottingham C, Schwen ZR, Thomas S, Fishman EK, Lee NJ, Pierorazio PM, Eggener SE. Clinical and Radiographic Predictors of Great Vessel Resection or Reconstruction During Retroperitoneal Lymph Node Dissection for Testicular Cancer. Urology. 2019 01; 123:186-190. PMID: 30179635.
      Citations: 5     Fields:    Translation:Humans
    117. Riedinger CB, Labbate C, Werntz RP, Eggener SE. Late Relapse of Nonseminomatous Germ Cell Tumor 24 Years Later. Urology. 2018 Dec; 122:16-18. PMID: 30170087.
      Citations:    Fields:    Translation:Humans
    118. Westin C, Chatterjee A, Ku E, Yousuf A, Wang S, Thomas S, Fan X, Eggener S, Karczmar G, Oto A. MRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer. AJR Am J Roentgenol. 2018 09; 211(3):595-604. PMID: 29995499.
      Citations: 7     Fields:    Translation:Humans
    119. Barashi NS, Pearce SM, Cohen AJ, Pariser JJ, Packiam VT, Eggener SE. Incidence, Risk Factors, and Outcomes for Rectal Injury During Radical Prostatectomy: A Population-based Study. Eur Urol Oncol. 2018 12; 1(6):501-506. PMID: 31158094.
      Citations: 5     Fields:    Translation:Humans
    120. Lodeizen O, de Bruin M, Eggener S, Ghai S, Varkarakis I, Katz A, Dominguez-Escrig JL, Pahernik S, de Reijke T, de la Rosette J, Crouzet S. Ablation energies for focal treatment of prostate cancer. World J Urol. 2019 Mar; 37(3):409-418. PMID: 29943219; PMCID: PMC6424940.
      Citations: 19     Fields:    Translation:Humans
    121. Tretiakova M, Mehta V, Kocherginsky M, Minor A, Shen SS, Sirintrapun SJ, Yao JL, Alvarado-Cabrero I, Antic T, Eggener SE, Picken MM, Paner GP. Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum. Virchows Arch. 2018 Jul; 473(1):85-93. PMID: 29770853.
      Citations: 9     Fields:    Translation:Humans
    122. Packiam VT, Nottingham CU, Cohen AJ, Eggener SE, Gerber GS. No Effect of Music on Anxiety and Pain During Transrectal Prostate Biopsies: A Randomized Trial. Urology. 2018 Jul; 117:31-35. PMID: 29709434.
      Citations: 9     Fields:    Translation:Humans
    123. Dinizo M, Shih W, Kwon YS, Eun D, Reese A, Giusto L, Trabulsi EJ, Yuh B, Ruel N, Marchalik D, Hwang J, Kundu SD, Eggener S, Kim IY. Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance. Oncotarget. 2018 Apr 20; 9(30):21359-21365. PMID: 29765545; PMCID: PMC5940363.
      Citations: 6     Fields:    
    124. Dall'Era MA, Davies BJ, Eggener S. Active surveillance for prostate cancer. Transl Androl Urol. 2018 Apr; 7(2):195-196. PMID: 29732276; PMCID: PMC5911535.
      Citations:    
    125. PRECISION Study Group Collaborators, Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May 10; 378(19):1767-1777. PMID: 29552975; PMCID: PMC9084630.
      Citations: 971     Fields:    Translation:Humans
    126. Werntz RP, Eggener SE. Novel focal therapy treatment options for prostate cancer. Curr Opin Urol. 2018 03; 28(2):178-183. PMID: 29232270.
      Citations: 3     Fields:    Translation:Humans
    127. Browne JA, Leir SH, Eggener SE, Harris A. Region-specific innate antiviral responses of the human epididymis. Mol Cell Endocrinol. 2018 09 15; 473:72-78. PMID: 29339104; PMCID: PMC6045438.
      Citations: 5     Fields:    Translation:HumansCells
    128. Pieczonka CM, Twardowski P, Renzulli J, Hafron J, Boldt-Houle DM, Atkinson S, Eggener S. Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients. Rev Urol. 2018; 20(2):63-68. PMID: 30288142; PMCID: PMC6168320.
      Citations: 5     
    129. Eggener S. Focal Therapy for Localized Prostate Cancer. Rev Urol. 2018; 20(4):143-144. PMID: 30787672; PMCID: PMC6375004.
      Citations: 1     
    130. Bernstein AN, Shoag JE, Golan R, Halpern JA, Schaeffer EM, Hsu WC, Nguyen PL, Sedrakyan A, Chen RC, Eggener SE, Hu JC. Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases. J Urol. 2018 06; 199(6):1510-1517. PMID: 29288121; PMCID: PMC6530582.
      Citations: 24     Fields:    Translation:Humans
    131. Smith ZL, Werntz RP, Eggener SE. Testicular Cancer: Epidemiology, Diagnosis, and Management. Med Clin North Am. 2018 Mar; 102(2):251-264. PMID: 29406056.
      Citations: 74     Fields:    Translation:Humans
    132. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 02 01; 36(4):414-424. PMID: 29236593; PMCID: PMC6075860.
      Citations: 76     Fields:    Translation:Humans
    133. Eggener S. Nodal Metastases at Radical Prostatectomy: More Aggressive Disease Warrants Consideration of Multimodal Treatment. Eur Urol. 2018 06; 73(6):897-898. PMID: 29224914.
      Citations:    Fields:    Translation:Humans
    134. Weiner AB, Matulewicz RS, Schaeffer EM, Liauw SL, Feinglass JM, Eggener SE. Contemporary management of men with high-risk localized prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2017 12; 20(4):442. PMID: 29125150.
      Citations: 5     Fields:    
    135. Rodriguez JF, Eggener SE. Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis. Radiol Clin North Am. 2018 Mar; 56(2):187-196. PMID: 29420975.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    136. Eggener S. Can Focal Treatment Replace Radical Treatment in Prostate Cancer? For Focal Therapy. Eur Urol Focus. 2017 12; 3(6):522-523. PMID: 29174615.
      Citations:    Fields:    Translation:Humans
    137. Packiam VT, Eggener SE. Minimal difference in survival between radical prostatectomy and observation in men with modest life expectancy. Evid Based Med. 2017 12; 22(6):222. PMID: 29127213.
      Citations:    Fields:    Translation:Humans
    138. Rodriguez JF, Liauw SL, Eggener SE. Managing Cancer Relapse After Radical Prostatectomy: Adjuvant Versus Salvage Radiation Therapy. Urol Clin North Am. 2017 Nov; 44(4):597-609. PMID: 29107276.
      Citations:    Fields:    Translation:Humans
    139. Wenger H, Razmaria A, Eggener S, Raman JD. Nerve Bundle Hydrodissection and Sexual Function after Robot Prostatectomy. JSLS. 2017 Oct-Dec; 21(4). PMID: 29279663; PMCID: PMC5740780.
      Citations: 1     Fields:    Translation:Humans
    140. Smith ZL, Eggener SE. In localised prostate cancer, radical prostatectomy was associated with more sexual dysfunction and urinary incontinence than radiation or active surveillance. Evid Based Med. 2017 10; 22(5):192. PMID: 28814450.
      Citations: 1     Fields:    Translation:Humans
    141. Smith ZL, Eggener SE, Murphy AB. African-American Prostate Cancer Disparities. Curr Urol Rep. 2017 Aug 14; 18(10):81. PMID: 28808871.
      Citations: 57     Fields:    Translation:Humans
    142. Chow AK, Sherer BA, Yura E, Kielb S, Kocjancic E, Eggener S, Turk T, Park S, Psutka S, Abern M, Latchamsetty KC, Coogan CL. Urology Residents' Experience and Attitude Toward Surgical Simulation: Presenting our 4-Year Experience With a Multi-institutional, Multi-modality Simulation Model. Urology. 2017 Nov; 109:32-37. PMID: 28801218.
      Citations: 2     Fields:    
    143. Weiner AB, Matulewicz RS, Schaeffer EM, Liauw SL, Feinglass JM, Eggener SE. Contemporary management of men with high-risk localized prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2017 09; 20(3):283-288. PMID: 28631720.
      Citations: 10     Fields:    Translation:Humans
    144. Tallman JE, Pearce SM, Kuchta K, Helfand BT, Eggener SE. Impact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma. J Urol. 2017 11; 198(5):1027-1032. PMID: 28551443.
      Citations: 1     Fields:    Translation:Humans
    145. Fulgham PF, Rukstalis DB, Turkbey IB, Rubenstein JN, Taneja S, Carroll PR, Pinto PA, Bjurlin MA, Eggener S. AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2017 10; 198(4):832-838. PMID: 28483574; PMCID: PMC7905434.
      Citations: 38     Fields:    Translation:HumansPHPublic Health
    146. Wymer KM, Daneshmand S, Pierorazio PM, Pearce SM, Harris KT, Eggener SE. Mildly elevated serum alpha-fetoprotein (AFP) among patients with testicular cancer may not be associated with residual cancer or need for treatment. Ann Oncol. 2017 04 01; 28(4):899-902. PMID: 28137740.
      Citations: 7     Fields:    Translation:Humans
    147. Ericson KJ, Wenger HC, Rosen AM, Kiriluk KJ, Gerber GS, Paner GP, Eggener SE. Prostate cancer detection following diagnosis of atypical small acinar proliferation. Can J Urol. 2017 Apr; 24(2):8714-8720. PMID: 28436357.
      Citations: 3     Fields:    Translation:HumansCells
    148. Moschini M, Carroll PR, Eggener SE, Epstein JI, Graefen M, Montironi R, Parker C. Low-risk Prostate Cancer: Identification, Management, and Outcomes. Eur Urol. 2017 08; 72(2):238-249. PMID: 28318726.
      Citations: 29     Fields:    Translation:Humans
    149. Tallman JE, Packiam VT, Wroblewski KE, Paner GP, Eggener SE. Influence of pathologist experience on positive surgical margins following radical prostatectomy. Urol Oncol. 2017 07; 35(7):461.e1-461.e6. PMID: 28302349; PMCID: PMC5476525.
      Citations: 4     Fields:    Translation:Humans
    150. Kane CJ, Eggener SE, Shindel AW, Andriole GL. Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review. Eur Urol Focus. 2017 10; 3(4-5):487-497. PMID: 28753804.
      Citations: 31     Fields:    Translation:Humans
    151. Verma S, Rosenkrantz AB, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, Haider MA, Margolis DJ, Marks LS, Pinto P, Sonn GA, Taneja SS. Commentary regarding a recent collaborative consensus statement addressing prostate MRI and MRI-targeted biopsy in patients with a prior negative prostate biopsy. Abdom Radiol (NY). 2017 Feb; 42(2):346-349. PMID: 27670878.
      Citations: 5     Fields:    Translation:Humans
    152. Finelli A, Ismaila N, Bro B, Durack J, Eggener S, Evans A, Gill I, Graham D, Huang W, Jewett MA, Latcha S, Lowrance W, Rosner M, Shayegan B, Thompson RH, Uzzo R, Russo P. Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 Feb 20; 35(6):668-680. PMID: 28095147.
      Citations: 94     Fields:    Translation:Humans
    153. Anderson BB, Oberlin DT, Razmaria AA, Choy B, Zagaja GP, Shalhav AL, Meeks JJ, Yang XJ, Paner GP, Eggener SE. Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer. Eur Urol. 2017 09; 72(3):455-460. PMID: 27986368.
      Citations: 14     Fields:    Translation:Humans
    154. Eggener S. Generalizability of Clinical Trials: Why It Matters for Patients and Public Policy. Eur Urol. 2017 04; 71(4):515-516. PMID: 27743755.
      Citations: 3     Fields:    Translation:Humans
    155. Murthy P, Malik RD, McCammon KA, Schneck FX, deVries C, Chrouser K, Eggener SE. Perspectives on International Urological Volunteerism: A Survey of IVUmed Resident Scholar Alumni. Urol Pract. 2017 Mar; 4(2):176-182. PMID: 37592674.
      Citations: 1     Fields:    
    156. Pearce SM, Anderson BB, Shalhav AL, Zagaja G, Eggener SE, Paner GP, Choy B. Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy. Am J Surg Pathol. 2016 10; 40(10):1400-6. PMID: 27379821.
      Citations: 40     Fields:    Translation:Humans
    157. Wenger H, Weiner AB, Razmaria A, Paner GP, Eggener SE. Risk of lymph node metastases in pathological gleason score=6 prostate adenocarcinoma: Analysis of institutional and population-based databases. Urol Oncol. 2017 01; 35(1):31.e1-31.e6. PMID: 27692833.
      Citations: 7     Fields:    Translation:Humans
    158. Wymer KM, Pearce SM, Harris KT, Pierorazio PM, Daneshmand S, Eggener SE. Adherence to National Comprehensive Cancer Network® Guidelines for Testicular Cancer. J Urol. 2017 03; 197(3 Pt 1):684-689. PMID: 27663460.
      Citations: 24     Fields:    Translation:Humans
    159. Weiner AB, Pearce SM, Eggener SE. Management trends for men with early-stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database. Cancer. 2017 01 01; 123(2):245-252. PMID: 27626903.
      Citations: 4     Fields:    Translation:Humans
    160. Eggener SE. Editorial Comment. J Urol. 2016 12; 196(6):1668-1669. PMID: 27613117.
      Citations:    Fields:    Translation:Humans
    161. Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, Emberton M. New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Eur Urol. 2017 01; 71(1):17-34. PMID: 27595377.
      Citations: 105     Fields:    Translation:Humans
    162. Eggener SE, Yousuf A, Watson S, Wang S, Oto A. Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer. J Urol. 2016 12; 196(6):1670-1675. PMID: 27449263.
      Citations: 54     Fields:    Translation:HumansCTClinical Trials
    163. Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis. 2016 12; 19(4):395-397. PMID: 27431496.
      Citations: 115     Fields:    Translation:Humans
    164. Packiam VT, Nottingham CU, Cohen AJ, Pearce SM, Shalhav AL, Eggener SE. The Impact of Perioperative Aspirin on Bleeding Complications Following Robotic Partial Nephrectomy. J Endourol. 2016 09; 30(9):997-1003. PMID: 27338841.
      Citations:    Fields:    Translation:Humans
    165. Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, Haider MA, Margolis DJ, Marks LS, Pinto P, Sonn GA, Taneja SS. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol. 2016 12; 196(6):1613-1618. PMID: 27320841; PMCID: PMC6364689.
      Citations: 102     Fields:    Translation:Humans
    166. Browne JA, Yang R, Eggener SE, Leir SH, Harris A. Erratum to "HNF1 regulates critical processes in the human epididymis epithelium" [Mol. Cell. Endocrinol. 425 (2016) 94-102]. Mol Cell Endocrinol. 2016 Jun 15; 428:174. PMID: 27147477.
      Citations:    Fields:    
    167. Pearce SM, Golan S, Gorin MA, Luckenbaugh AN, Williams SB, Ward JF, Montgomery JS, Hafez KS, Weizer AZ, Pierorazio PM, Allaf ME, Eggener SE. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. Eur Urol. 2017 03; 71(3):476-482. PMID: 27234998.
      Citations: 35     Fields:    Translation:Humans
    168. Drazer MW, Eggener SE. Patient-Initiated Prostate Cancer Screening Among Older U.S. Men. Ann Intern Med. 2016 05 17; 164(10):702-3. PMID: 27182910.
      Citations:    Fields:    Translation:HumansPHPublic Health
    169. Postema AW, De Reijke TM, Ukimura O, Van den Bos W, Azzouzi AR, Blana A, Bossi A, Brausi M, Coleman JA, Crouzet S, Eggener S, Ganzer R, Ghai S, Gill IS, Gupta RT, Henkel TO, Hohenfellner M, Jones JS, Kahmann F, Kastner C, Miano R, van Moorselaar RJ, Osorio L, Pieters BR, Polascik TJ, Rastinehad AR, Salomon G, Sentker L, Tay KJ, Varkarakis IM, Villers A, Walz J, De la Rosette JJ, Barret E, Baumunk D, Dominguez-Escrig J, Köhrmann KU, Kovacs G, Mottet N, Sanchez-Salas R, Schostak M. Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. World J Urol. 2016 Oct; 34(10):1373-82. PMID: 26892160; PMCID: PMC5026990.
      Citations: 23     Fields:    Translation:Humans
    170. Pearce SM, Pariser JJ, Karrison T, Patel SG, Eggener SE. Comparison of Perioperative and Early Oncologic Outcomes between Open and Robotic Assisted Laparoscopic Prostatectomy in a Contemporary Population Based Cohort. J Urol. 2016 07; 196(1):76-81. PMID: 26860793.
      Citations: 27     Fields:    Translation:Humans
    171. Browne JA, Yang R, Eggener SE, Leir SH, Harris A. HNF1 regulates critical processes in the human epididymis epithelium. Mol Cell Endocrinol. 2016 Apr 15; 425:94-102. PMID: 26808453; PMCID: PMC4799753.
      Citations: 10     Fields:    Translation:HumansCells
    172. Son CH, Melotek JM, Liao C, Hubert G, Pelizzari CA, Eggener SE, Liauw SL. Bladder dose-volume parameters are associated with urinary incontinence after postoperative intensity modulated radiation therapy for prostate cancer. Pract Radiat Oncol. 2016 Sep-Oct; 6(5):e179-e185. PMID: 26961716.
      Citations: 3     Fields:    Translation:Humans
    173. Weiner AB, Conti RM, Eggener SE. National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions. J Urol. 2016 May; 195(5):1383-1389. PMID: 26707507.
      Citations: 5     Fields:    Translation:Humans
    174. Valerio M, Emberton M, Eggener SE, Ahmed HU. The challenging landscape of medical device approval in localized prostate cancer. Nat Rev Urol. 2016 Feb; 13(2):91-8. PMID: 26666364.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    175. Browne JA, Yang R, Leir SH, Eggener SE, Harris A. Expression profiles of human epididymis epithelial cells reveal the functional diversity of caput, corpus and cauda regions. Mol Hum Reprod. 2016 Feb; 22(2):69-82. PMID: 26612782; PMCID: PMC4733224.
      Citations: 36     Fields:    Translation:HumansCells
    176. Ward JF, Eggener SE. Active surveillance monitoring: the role of novel biomarkers and imaging. Asian J Androl. 2015 Nov-Dec; 17(6):882-4; discussion 883. PMID: 26112488; PMCID: PMC4814962.
      Citations: 2     Fields:    Translation:Humans
    177. Golan S, Eggener S, Subotic S, Cormio L, Naito S, Tefekli A, Pilar Laguna Pes M, Barret E. Prediction of renal mass aggressiveness using clinical and radiographic features: a global, multicentre prospective study. BJU Int. 2016 06; 117(6):914-22. PMID: 26389787.
      Citations: 3     Fields:    Translation:Humans
    178. Ledezma RA, Negron E, Paner GP, Rjepaj C, Lascano D, Haseebuddin M, Dangle P, Shalhav AL, Crist H, Raman JD, Joel DeCastro G, Harik L, Paroder M, Uzzo RG, Kutikov A, Eggener SE. Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. World J Urol. 2016 May; 34(5):687-93. PMID: 26407582.
      Citations: 12     Fields:    Translation:Humans
    179. Eggener S. Prostate Cancer Screening Biomarkers: An Emerging Embarrassment of 'Riches'? Eur Urol. 2016 07; 70(1):54-55. PMID: 26382084.
      Citations: 5     Fields:    Translation:Humans
    180. Eggener SE, Cifu AS, Nabhan C. Prostate Cancer Screening. JAMA. 2015 Aug 25; 314(8):825-6. PMID: 26305653.
      Citations: 12     Fields:    Translation:Humans
    181. Eggener S. Known Knowns, Known Unknowns, and Unknown Unknowns of High-intensity Focused Ultrasound for Prostate Cancer. Eur Urol Focus. 2015 Sep; 1(2):171-172. PMID: 28723430.
      Citations:    Fields:    
    182. Packiam VT, Patel SG, Pariser JJ, Richards KA, Weiner AB, Paner GP, VanderWeele DJ, Zagaja GP, Eggener SE. Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. Urology. 2015 Oct; 86(4):777-82. PMID: 26196240.
      Citations: 11     Fields:    Translation:HumansPHPublic Health
    183. Baad M, Ericson K, Yassan L, Oto A, Eggener S, Nottingham CU, Richards KA, Thomas S. Giant Multilocular Cystadenoma of the Prostate. Radiographics. 2015 Jul-Aug; 35(4):1051-5. PMID: 26172350.
      Citations: 7     Fields:    Translation:Humans
    184. Drazer MW, Huo D, Eggener SE. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. J Clin Oncol. 2015 Aug 01; 33(22):2416-23. PMID: 26056181.
      Citations: 77     Fields:    Translation:HumansPHPublic Health
    185. Pearce SM, Liauw SL, Eggener SE. Management of Low-Stage Testicular Seminoma. Urol Clin North Am. 2015 Aug; 42(3):287-98. PMID: 26216816.
      Citations: 4     Fields:    Translation:Humans
    186. Pearce SM, Pariser JJ, Patel SG, Anderson BB, Eggener SE, Zagaja GP. The impact of days off between cases on perioperative outcomes for robotic-assisted laparoscopic prostatectomy. World J Urol. 2016 Feb; 34(2):269-74. PMID: 26045402.
      Citations: 4     Fields:    Translation:Humans
    187. Sampat A, Parakati I, Kunnavakkam R, Glick DB, Lee NK, Tenney M, Eggener S, Roth S. Corneal abrasion in hysterectomy and prostatectomy: role of laparoscopic and robotic assistance. Anesthesiology. 2015 May; 122(5):994-1001. PMID: 25734923; PMCID: PMC5836305.
      Citations: 5     Fields:    Translation:Humans
    188. Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, Cooperberg MR, Boström PJ, Bjartell AS. Genomic Predictors of Outcome in Prostate Cancer. Eur Urol. 2015 Dec; 68(6):1033-44. PMID: 25913390.
      Citations: 88     Fields:    Translation:Humans
    189. Golan S, Eggener S. EVALUATING THE EMERGING TRENDS IN THE DIAGNOSIS AND TREATMENT OF KIDNEY CANCER—THE RENAL MASS GLOBAL STUDY. J Endourol. 2015 May; 29(5):495-7. PMID: 25884106.
      Citations: 1     Fields:    
    190. Eggener SE, Badani K, Barocas DA, Barrisford GW, Cheng JS, Chin AI, Corcoran A, Epstein JI, George AK, Gupta GN, Hayn MH, Kauffman EC, Lane B, Liss MA, Mirza M, Morgan TM, Moses K, Nepple KG, Preston MA, Rais-Bahrami S, Resnick MJ, Siddiqui MM, Silberstein J, Singer EA, Sonn GA, Sprenkle P, Stratton KL, Taylor J, Tomaszewski J, Tollefson M, Vickers A, White WM, Lowrance WT. Gleason 6 Prostate Cancer: Translating Biology into Population Health. J Urol. 2015 Sep; 194(3):626-34. PMID: 25849602; PMCID: PMC4551510.
      Citations: 36     Fields:    Translation:Humans
    191. Ledezma RA, Negron E, Razmaria AA, Dangle P, Eggener SE, Shalhav AL, Zagaja GP. Robotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes. World J Urol. 2015 Nov; 33(11):1689-94. PMID: 25701128.
      Citations: 5     Fields:    Translation:Humans
    192. Pearce SM, Richards KA, Patel SG, Pariser JJ, Eggener SE. Population-based analysis of salvage radical prostatectomy with examination of factors associated with adverse perioperative outcomes. Urol Oncol. 2015 Apr; 33(4):163.e1-6. PMID: 25708953.
      Citations: 5     Fields:    Translation:Humans
    193. Loeb S, Bayne CE, Frey C, Davies BJ, Averch TD, Woo HH, Stork B, Cooperberg MR, Griebling TL, Eggener SE, American Urological Association Social Media Work Group. Updated Survey of Social Media Use by Members of the American Urological Association. Urol Pract. 2015 May; 2(3):138-143. PMID: 37559256.
      Citations: 4     Fields:    
    194. Eggener S. How active should active surveillance be? BJU Int. 2015 Feb; 115(2):176-7. PMID: 25604714.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    195. Weiner AB, Murthy P, Richards KA, Patel SG, Eggener SE. Population based analysis of incidence and predictors of open conversion during minimally invasive radical prostatectomy. J Urol. 2015 Mar; 193(3):826-31. PMID: 25632850.
      Citations: 4     Fields:    Translation:Humans
    196. Weiner AB, Patel SG, Eggener SE. Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States. Urol Oncol. 2015 Apr; 33(4):164.e11-7. PMID: 25624093.
      Citations: 14     Fields:    Translation:Humans
    197. Leir SH, Browne JA, Eggener SE, Harris A. Characterization of primary cultures of adult human epididymis epithelial cells. Fertil Steril. 2015 Mar; 103(3):647-54.e1. PMID: 25542823; PMCID: PMC4346407.
      Citations: 17     Fields:    Translation:HumansCells
    198. Gabr AH, Steinberg Z, Eggener SE, Stuart Wolf J. Indications for adrenalectomy during radical nephrectomy for renal cancer. Arab J Urol. 2014 Dec; 12(4):304-8. PMID: 26019967; PMCID: PMC4434884.
      Citations: 1     
    199. Bachrach L, Negron E, Liu JS, Su YK, Paparello JJ, Eggener S, Kundu SD. Preoperative nuclear renal scan underestimates renal function after radical nephrectomy. Urology. 2014 Dec; 84(6):1402-6. PMID: 25312551.
      Citations: 4     Fields:    Translation:Humans
    200. Donaldson IA, Alonzi R, Barratt D, Barret E, Berge V, Bott S, Bottomley D, Eggener S, Ehdaie B, Emberton M, Hindley R, Leslie T, Miners A, McCartan N, Moore CM, Pinto P, Polascik TJ, Simmons L, van der Meulen J, Willis S, Ahmed HU, Villers A. Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting. Eur Urol. 2015 Apr; 67(4):771-7. PMID: 25281389; PMCID: PMC4410301.
      Citations: 77     Fields:    Translation:Humans
    201. Richards KA, Negron E, Cohn JA, Steinberg Z, Eggener SE, Shalhav AL. The impact of body mass index on renal functional outcomes following minimally invasive partial nephrectomy. J Endourol. 2014 Nov; 28(11):1338-44. PMID: 24935823; PMCID: PMC4382827.
      Citations: 4     Fields:    Translation:Humans
    202. Weiner AB, Patel SG, Etzioni R, Eggener SE. National trends in the management of low and intermediate risk prostate cancer in the United States. J Urol. 2015 Jan; 193(1):95-102. PMID: 25106900.
      Citations: 35     Fields:    Translation:Humans
    203. Eggener S. Commentary on "Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare." Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM, Department of Urology, New York University, New York, NY. J Urol 2013; 189(3):867-70. [Epub 2012 Oct 9]. doi: 10.1016/j.juro.2012.10.005. Urol Oncol. 2014 Aug; 32(6):935-6. PMID: 25087672.
      Citations: 1     Fields:    Translation:Humans
    204. Eggener S. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. N Engl J Med 2013; 368(14):1314-25. doi: 10.1056/NEJMoa1212299. Urol Oncol. 2014 Aug; 32(6):936-7. PMID: 25087673.
      Citations: 2     Fields:    Translation:Humans
    205. Eggener S. Commentary on "African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?" Sundi D, Ross AE, Humphreys EB, Han M, Partin AW, Carter HB, Schaeffer EM, Johns Hopkins University, Baltimore, MD. J Clin Oncol 2013; 31(24):2991-7. [Epub 2013 Jun 17]. doi: 10.1200/JCO.2012.47.0302. Urol Oncol. 2014 Aug; 32(6):936. PMID: 25087674.
      Citations:    Fields:    Translation:Humans
    206. Nigam M, Aschebrook-Kilfoy B, Shikanov S, Eggener S. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol. 2015 May; 33(5):623-31. PMID: 25030752.
      Citations: 48     Fields:    Translation:Humans
    207. Cohen A, Richards KA, Patel S, Weiner A, Eggener SE, Szmulewitz RZ. Metastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms. Urol Oncol. 2015 Feb; 33(2):70.e1-7. PMID: 25044254.
      Citations: 5     Fields:    Translation:Humans
    208. Weiner AB, Patel SG, Richards KA, Szmulewitz RZ, Eggener SE. Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):286-91. PMID: 25027862.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    209. Hu JC, Williams SB, Carter SC, Eggener SE, Prasad S, Chamie K, Trinh QD, Nguyen PL, Lipsitz SR, Sun M. Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. Urol Oncol. 2015 Feb; 33(2):69.e29-34. PMID: 25017694.
      Citations: 6     Fields:    Translation:Humans
    210. Prasad SM, Eggener SE, Lipsitz SR, Irwin MR, Ganz PA, Hu JC. Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer. J Clin Oncol. 2014 Aug 10; 32(23):2471-8. PMID: 25002728; PMCID: PMC4121505.
      Citations: 57     Fields:    Translation:Humans
    211. Valerio M, Emberton M, Barret E, Eberli D, Eggener SE, Ehdaie B, Jichlinski P, Ward JF, Ahmed HU. Health technology assessment in evolution - focal therapy in localised prostate cancer. Expert Rev Anticancer Ther. 2014 Nov; 14(11):1359-67. PMID: 24965212.
      Citations: 3     Fields:    Translation:Humans
    212. Loeb S, Bayne CE, Frey C, Davies BJ, Averch TD, Woo HH, Stork B, Cooperberg MR, Eggener SE, American Urological Association Social Media Work Group. Use of social media in urology: data from the American Urological Association (AUA). BJU Int. 2014 Jun; 113(6):993-8. PMID: 24274744.
      Citations: 41     Fields:    Translation:Humans
    213. Eggener SE, Clark MA, Shikanov S, Smith B, Kaag M, Russo P, Wheat JC, Wolf JS, Matin SF, Huang WC, Harel M, Cambio J, Shalhav AL, Raman JD. Impact of warm versus cold ischemia on renal function following partial nephrectomy. World J Urol. 2015 Mar; 33(3):351-7. PMID: 24817142.
      Citations: 5     Fields:    Translation:Humans
    214. Hansford BG, Karademir I, Peng Y, Jiang Y, Karczmar G, Thomas S, Yousuf A, Antic T, Eggener S, Oto A. Dynamic contrast-enhanced MR imaging features of the normal central zone of the prostate. Acad Radiol. 2014 May; 21(5):569-77. PMID: 24703469.
      Citations: 6     Fields:    Translation:Humans
    215. Eggener S. Commentary on: "Long-term functional outcomes after treatment for localized prostate cancer." Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Department of Urologic Surgery and the Center for Surgical Quality and Outcomes Research, Vanderbilt University, Nashville, TN.: N Engl J Med 2013;368(5):436-45. doi: 10.1056/NEJMoa1209978. Urol Oncol. 2014 May; 32(4):513-4. PMID: 24767688.
      Citations: 4     Fields:    Translation:Humans
    216. Wenger H, Yousuf A, Oto A, Eggener S. Laser ablation as focal therapy for prostate cancer. Curr Opin Urol. 2014 May; 24(3):236-40. PMID: 24625427; PMCID: PMC4071166.
      Citations: 14     Fields:    Translation:HumansAnimals
    217. Eggener S. Elastographic search for the (high-grade) tree in the (prostatic) forest. BJU Int. 2014 Apr; 113(4):514-5. PMID: 24629082.
      Citations:    Fields:    Translation:Humans
    218. Eggener S. Editorial comment. J Urol. 2014 Jul; 192(1):81. PMID: 24703979.
      Citations:    Fields:    Translation:Humans
    219. Li G, Ci W, Karmakar S, Chen K, Dhar R, Fan Z, Guo Z, Zhang J, Ke Y, Wang L, Zhuang M, Hu S, Li X, Zhou L, Li X, Calabrese MF, Watson ER, Prasad SM, Rinker-Schaeffer C, Eggener SE, Stricker T, Tian Y, Schulman BA, Liu J, White KP. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell. 2014 Apr 14; 25(4):455-68. PMID: 24656772; PMCID: PMC4443692.
      Citations: 97     Fields:    Translation:HumansAnimalsCells
    220. Weiner AB, Etzioni R, Eggener SE. Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance. Eur Urol. 2014 Oct; 66(4):611-2. PMID: 24630416; PMCID: PMC4155020.
      Citations: 6     Fields:    Translation:Humans
    221. Peng Y, Jiang Y, Antic T, Sethi I, Schmid-Tannwald C, Eggener S, Oto A. Apparent diffusion coefficient for prostate cancer imaging: impact of B values. AJR Am J Roentgenol. 2014 Mar; 202(3):W247-53. PMID: 24555621.
      Citations: 19     Fields:    Translation:Humans
    222. Smid MC, Bhardwaj NR, Di Giovanni LM, Eggener S, Torre MD. Renal hemorrhagic actinomycotic abscess in pregnancy. Infect Dis Rep. 2014 Feb 18; 6(1):5157. PMID: 24757509; PMCID: PMC3987246.
      Citations: 2     
    223. Drazer MW, Prasad SM, Huo D, Schonberg MA, Dale W, Szmulewitz RZ, Eggener SE. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer. 2014 May 15; 120(10):1491-8. PMID: 24523016.
      Citations: 35     Fields:    Translation:HumansPHPublic Health
    224. Peng Y, Jiang Y, Antic T, Giger ML, Eggener SE, Oto A. Validation of quantitative analysis of multiparametric prostate MR images for prostate cancer detection and aggressiveness assessment: a cross-imager study. Radiology. 2014 May; 271(2):461-71. PMID: 24533870.
      Citations: 30     Fields:    Translation:Humans
    225. van den Bos W, Muller BG, Ahmed H, Bangma CH, Barret E, Crouzet S, Eggener SE, Gill IS, Joniau S, Pahernik S, de la Rosette JJ, Salomon G, Ward JF, Scardino PT, Kovacs G, Rouvière O. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol. 2014 Jun; 65(6):1078-83. PMID: 24444476.
      Citations: 71     Fields:    Translation:Humans
    226. Golan S, Patel AR, Eggener SE, Shalhav AL. The volume of nonneoplastic parenchyma in a minimally invasive partial nephrectomy specimen: predictive factors and impact on renal function. J Endourol. 2014 Feb; 28(2):196-200. PMID: 24033335.
      Citations: 5     Fields:    Translation:Humans
    227. Karademir I, Shen D, Peng Y, Liao S, Jiang Y, Yousuf A, Karczmar G, Sammet S, Wang S, Medved M, Antic T, Eggener S, Oto A. Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer. AJR Am J Roentgenol. 2013 Nov; 201(5):1041-8. PMID: 24147475; PMCID: PMC4354695.
      Citations: 17     Fields:    Translation:Humans
    228. Hansford BG, Peng Y, Jiang Y, Al-Ahmadie H, Eggener S, Yousuf A, Oto A. Revisiting the central gland anatomy via MRI: does the central gland extend below the level of verumontanum? J Magn Reson Imaging. 2014 Jan; 39(1):167-71. PMID: 24123318.
      Citations:    Fields:    Translation:Humans
    229. Pearce S, Steinberg Z, Eggener S. Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection. Curr Urol Rep. 2013 Oct; 14(5):511-7. PMID: 23907555.
      Citations: 9     Fields:    Translation:Humans
    230. Patel A, Golan S, Razmaria A, Prasad S, Eggener S, Shalhav A. Early discharge after laparoscopic or robotic partial nephrectomy: care pathway evaluation. BJU Int. 2014 Apr; 113(4):592-7. PMID: 24006926.
      Citations: 8     Fields:    Translation:Humans
    231. Truong M, Slezak JA, Lin CP, Iremashvili V, Sado M, Razmaria AA, Leverson G, Soloway MS, Eggener SE, Abel EJ, Downs TM, Jarrard DF. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer. 2013 Nov 15; 119(22):3992-4002. PMID: 24006289; PMCID: PMC4880351.
      Citations: 34     Fields:    Translation:Humans
    232. Stephenson AJ, Eggener SE, Hernandez AV, Klein EA, Kattan MW, Wood DP, Rabah DM, Eastham JA, Scardino PT. Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. Eur Urol. 2014 Apr; 65(4):675-80. PMID: 24035631.
      Citations: 31     Fields:    Translation:Humans
    233. Eggener SE, Large MC, Gerber GS, Pettus J, Yossepowitch O, Smith ND, Kundu S, Kunnavakkam R, Zorn K, Raman JD. Empiric antibiotics for an elevated prostate-specific antigen (PSA) level: a randomised, prospective, controlled multi-institutional trial. BJU Int. 2013 Nov; 112(7):925-9. PMID: 23890317.
      Citations: 5     Fields:    Translation:Humans
    234. Yuh B, Artibani W, Heidenreich A, Kimm S, Menon M, Novara G, Tewari A, Touijer K, Wilson T, Zorn KC, Eggener SE. The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review. Eur Urol. 2014 May; 65(5):918-27. PMID: 23721959.
      Citations: 55     Fields:    Translation:Humans
    235. Richards K, Eggener S. Words of wisdom: Re: Do adenocarcinomas of the prostate with Gleason Score (GS) = 6 have the potential to metastasize to lymph nodes? Eur Urol. 2013 May; 63(5):960. PMID: 23541252.
      Citations:    Fields:    
    236. Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Gill IS, Grubb Iii RL, Hadaschik B, Klotz L, Margolis DJ, Marks LS, Melamed J, Oto A, Palmer SL, Pinto P, Puech P, Punwani S, Rosenkrantz AB, Schoots IG, Simon R, Taneja SS, Turkbey B, Ukimura O, van der Meulen J, Villers A, Watanabe Y, START Consortium, Fütterer JJ. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol. 2013 Oct; 64(4):544-52. PMID: 23537686.
      Citations: 156     Fields:    Translation:Humans
    237. Oto A, Sethi I, Karczmar G, McNichols R, Ivancevic MK, Stadler WM, Watson S, Eggener S. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 2013 Jun; 267(3):932-40. PMID: 23440319.
      Citations: 75     Fields:    Translation:HumansCTClinical Trials
    238. Soylu FN, Peng Y, Jiang Y, Wang S, Schmid-Tannwald C, Sethi I, Eggener S, Antic T, Oto A. Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging. Radiology. 2013 Jun; 267(3):797-806. PMID: 23440325; PMCID: PMC6940014.
      Citations: 29     Fields:    Translation:Humans
    239. Peng Y, Jiang Y, Yang C, Brown JB, Antic T, Sethi I, Schmid-Tannwald C, Giger ML, Eggener SE, Oto A. Quantitative analysis of multiparametric prostate MR images: differentiation between prostate cancer and normal tissue and correlation with Gleason score--a computer-aided diagnosis development study. Radiology. 2013 Jun; 267(3):787-96. PMID: 23392430; PMCID: PMC6940008.
      Citations: 91     Fields:    Translation:Humans
    240. Lane BR, Golan S, Eggener S, Tobert CM, Kahnoski RJ, Kutikov A, Smaldone M, Whelan CM, Shalhav A, Uzzo RG. Differential use of partial nephrectomy for intermediate and high complexity tumors may explain variability in reported utilization rates. J Urol. 2013 Jun; 189(6):2047-53. PMID: 23313207.
      Citations: 12     Fields:    Translation:Humans
    241. Eggener SE, Mueller A, Berglund RK, Ayyathurai R, Soloway C, Soloway MS, Abouassaly R, Klein EA, Jones SJ, Zappavigna C, Goldenberg L, Scardino PT, Eastham JA, Guillonneau B. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol. 2013 Jan; 189(1 Suppl):S19-25; discussion S25. PMID: 23234624.
      Citations: 26     Fields:    Translation:Humans
    242. Breda A, Sanguedolce F, Landman J, Stolzenburg JU, Verze P, Rassweiler J, Van Poppel H, Klingler HC, Janetschek G, Celia A, Kim FJ, Thalmann G, Nagele U, Mogorovich A, Bolenz C, Knoll T, Porpiglia F, Alvarez-Maestro M, Francesca F, Deho F, Eggener S, Abbou C, Meng MV, Aron M, Laguna P, Mladenov D, D'Addessi A, Bove P, Schiavina R, De Cobelli O, Merseburger AS, Dalpiaz O, D'Ancona FC, Polascik TJ, Muschter R, Leppert TJ, Villavicencio H, Cosentino M. The use of mannitol in partial and live donor nephrectomy: an international survey. World J Urol. 2013 Aug; 31(4):977-82. PMID: 23242033.
      Citations: 16     Fields:    Translation:Humans
    243. Shikanov S, Marchetti P, Desai V, Razmaria A, Antic T, Al-Ahmadie H, Zagaja G, Eggener S, Brendler C, Shalhav A. Short (= 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy. BJU Int. 2013 Apr; 111(4):559-63. PMID: 22759270.
      Citations: 8     Fields:    Translation:Humans
    244. Liauw SL, Pitroda SP, Eggener SE, Stadler WM, Pelizzari CA, Vannier MW, Oto A. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):378-84. PMID: 22717242.
      Citations: 32     Fields:    Translation:Humans
    245. Corbin KS, Kunnavakkam R, Eggener SE, Liauw SL. Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality of life. Pract Radiat Oncol. 2013 Apr-Jun; 3(2):138-44. PMID: 24674317.
      Citations: 7     Fields:    
    246. Eggener S. Re: Active surveillance failure for prostate cancer: does the delay in treatment increase the risk of urinary incontinence? Can J Urol. 2012 Jun; 19(3):6292. PMID: 22704316.
      Citations:    Fields:    Translation:HumansPHPublic Health
    247. Yacoub JH, Verma S, Moulton JS, Eggener S, Aytekin O. Imaging-guided prostate biopsy: conventional and emerging techniques. Radiographics. 2012 May-Jun; 32(3):819-37. PMID: 22582361.
      Citations: 29     Fields:    Translation:Humans
    248. Prasad SM, Drazer MW, Huo D, Hu JC, Eggener SE. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA. 2012 Apr 25; 307(16):1692-4. PMID: 22535850.
      Citations: 16     Fields:    Translation:HumansPHPublic Health
    249. Patel AR, Prasad SM, Shih YC, Eggener SE. The association of the human development index with global kidney cancer incidence and mortality. J Urol. 2012 Jun; 187(6):1978-83. PMID: 22498216.
      Citations: 18     Fields:    Translation:Humans
    250. Smeenge M, Barentsz J, Cosgrove D, de la Rosette J, de Reijke T, Eggener S, Frauscher F, Kovacs G, Matin SF, Mischi M, Pinto P, Rastinehad A, Rouviere O, Salomon G, Polascik T, Walz J, Wijkstra H, Marberger M. Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. BJU Int. 2012 Oct; 110(7):942-8. PMID: 22462566.
      Citations: 35     Fields:    Translation:Humans
    251. Soylu FN, Eggener S, Oto A. Local staging of prostate cancer with MRI. Diagn Interv Radiol. 2012 Jul-Aug; 18(4):365-73. PMID: 22399364.
      Citations: 14     Fields:    Translation:Humans
    252. Meeks JJ, Sheinfeld J, Eggener SE. Environmental toxicology of testicular cancer. Urol Oncol. 2012 Mar-Apr; 30(2):212-5. PMID: 22385991.
      Citations: 7     Fields:    Translation:HumansAnimalsPHPublic Health
    253. Clements T, Messer JC, Terrell JD, Herman MP, Ng CK, Scherr DS, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, Lotan Y, Shariat SF, Raman JD. High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection. J Endourol. 2012 Apr; 26(4):398-402. PMID: 22192113.
      Citations: 32     Fields:    Translation:Humans
    254. Oto A, Yang C, Kayhan A, Tretiakova M, Antic T, Schmid-Tannwald C, Eggener S, Karczmar GS, Stadler WM. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol. 2011 Dec; 197(6):1382-90. PMID: 22109293.
      Citations: 92     Fields:    Translation:Humans
    255. Shikanov S, Eggener SE. Hazard of prostate cancer specific mortality after radical prostatectomy. J Urol. 2012 Jan; 187(1):124-7. PMID: 22114813.
      Citations: 2     Fields:    Translation:Humans
    256. Shikanov S, Kocherginsky M, Shalhav AL, Eggener SE. Cause-specific mortality following radical prostatectomy. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):106-10. PMID: 22083265.
      Citations: 28     Fields:    Translation:Humans
    257. Patel AR, Eggener SE. Warm ischemia less than 30 minutes is not necessarily safe during partial nephrectomy: every minute matters. Urol Oncol. 2011 Nov-Dec; 29(6):826-8. PMID: 22078406.
      Citations: 21     Fields:    Translation:Humans
    258. Fan X, Haney CR, Agrawal G, Pelizzari CA, Antic T, Eggener SE, Sethi I, River JN, Zamora M, Karczmar GS, Oto A. High-resolution MRI of excised human prostate specimens acquired with 9.4T in detection and identification of cancers: validation of a technique. J Magn Reson Imaging. 2011 Oct; 34(4):956-61. PMID: 21928309.
      Citations: 10     Fields:    Translation:Humans
    259. Marchetti P, Eggener S. Focal therapy for clinically localized prostate cancer. Arch Esp Urol. 2011 Oct; 64(8):815-22. PMID: 22052762.
      Citations: 1     Fields:    Translation:Humans
    260. Messer JC, Terrell JD, Herman MP, Ng CK, Scherr DS, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, Lotan Y, Shariat SF, Raman JD. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol. 2013 Aug; 31(6):904-8. PMID: 21906967.
      Citations: 34     Fields:    Translation:Humans
    261. Lifshitz DA, Shikanov SA, Razmaria AA, Eggener SE, Liao C, Chang A, Shalhav AL. Clinical and histologic predictors of renal function decline after laparoscopic partial nephrectomy. J Endourol. 2011 Sep; 25(9):1435-41. PMID: 21797760.
      Citations: 8     Fields:    Translation:Humans
    262. Rosen A, Jayram G, Drazer M, Eggener SE. Global trends in testicular cancer incidence and mortality. Eur Urol. 2011 Aug; 60(2):374-9. PMID: 21612857.
      Citations: 49     Fields:    Translation:Humans
    263. Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol. 2011 May 01; 29(13):1736-43. PMID: 21444863; PMCID: PMC4821471.
      Citations: 48     Fields:    Translation:HumansPHPublic Health
    264. Eggener S. Editorial comment. J Urol. 2011 Apr; 185(4):1254-5. PMID: 21334019.
      Citations:    Fields:    Translation:Humans
    265. Messer J, Shariat SF, Brien JC, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Steinberg G, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int. 2011 Sep; 108(5):701-5. PMID: 21320275.
      Citations: 78     Fields:    Translation:Humans
    266. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011 Mar; 185(3):869-75. PMID: 21239008; PMCID: PMC4058776.
      Citations: 229     Fields:    Translation:Humans
    267. Katz MH, Shikanov S, Sun M, Abdollah F, Budaeus L, Gong EM, Eggener SE, Steinberg GD, Zagaja GP, Shalhav AL, Karakiewicz PI, Zorn KC. Gleason 6 prostate cancer in one or two biopsy cores can harbor more aggressive disease. J Endourol. 2011 Apr; 25(4):699-703. PMID: 21226623.
      Citations: 2     Fields:    Translation:Humans
    268. Clark MA, Shikanov S, Raman JD, Smith B, Kaag M, Russo P, Wheat JC, Wolf JS, Matin SF, Huang WC, Shalhav AL, Eggener SE. Chronic kidney disease before and after partial nephrectomy. J Urol. 2011 Jan; 185(1):43-8. PMID: 21074205.
      Citations: 35     Fields:    Translation:Humans
    269. Shikanov S, Clark MA, Raman JD, Smith B, Kaag M, Russo P, Wheat JC, Wolf JS, Huang WC, Shalhav AL, Eggener SE. Chronic Kidney Disease Epidemiology Collaboration versus Modification of Diet in Renal Disease equations for renal function evaluation in patients undergoing partial nephrectomy. J Urol. 2010 Nov; 184(5):1867-71. PMID: 20846677.
      Citations: 4     Fields:    Translation:Humans
    270. Gautam G, Lifshitz D, Shikanov S, Moore JM, Eggener SE, Shalhav AL, Chang A. Histopathological predictors of renal function decrease after laparoscopic radical nephrectomy. J Urol. 2010 Nov; 184(5):1872-6. PMID: 20850146.
      Citations: 11     Fields:    Translation:Humans
    271. Eggener S. TNM staging for renal cell carcinoma: time for a new method. Eur Urol. 2010 Oct; 58(4):517-9; discussion 519-21. PMID: 20728266.
      Citations: 13     Fields:    Translation:Humans
    272. Eggener S, Salomon G, Scardino PT, De la Rosette J, Polascik TJ, Brewster S. Corrigendum to "Focal Therapy for Prostate Cancer: Possibilities and Limitations" [Eur Urol 2010;58:57-64]. Eur Urol. 2010 Oct; 58(4):644. PMID: 28065298.
      Citations: 1     Fields:    
    273. Brien JC, Shariat SF, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol. 2010 Jul; 184(1):69-73. PMID: 20478585.
      Citations: 77     Fields:    Translation:Humans
    274. Eggener S, Salomon G, Scardino PT, De la Rosette J, Polascik TJ, Brewster S. Focal therapy for prostate cancer: possibilities and limitations. Eur Urol. 2010 Jul; 58(1):57-64. PMID: 20378241.
      Citations: 24     Fields:    Translation:Humans
    275. Shikanov S, Lifshitz D, Chan AA, Okhunov Z, Ordonez MA, Wheat JC, Matin SF, Landman J, Wolf JS, Eggener SE, Shalhav AL. Impact of ischemia on renal function after laparoscopic partial nephrectomy: a multicenter study. J Urol. 2010 May; 183(5):1714-8. PMID: 20299052.
      Citations: 17     Fields:    Translation:Humans
    276. Carver BS, Cronin AM, Eggener S, Savage CJ, Motzer RJ, Bajorin D, Bosl GJ, Sheinfeld J. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology. 2010 Jun; 75(6):1431-5. PMID: 20299079; PMCID: PMC3654386.
      Citations: 15     Fields:    Translation:Humans
    277. Jayram G, Szmulewitz RZ, Eggener SE. Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: current concepts and controversies. Indian J Urol. 2010 Jan-Mar; 26(1):92-7. PMID: 20535293; PMCID: PMC2878446.
      Citations: 2     
    278. Large MC, Katz MH, Shikanov S, Eggener SE, Steinberg GD. Orthotopic neobladder versus Indiana pouch in women: a comparison of health related quality of life outcomes. J Urol. 2010 Jan; 183(1):201-6. PMID: 19913836.
      Citations: 8     Fields:    Translation:Humans
    279. Eggener S, Gonzalgo M, Yossepowitch O. Regarding: 'High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series'. Br J Cancer. 2009 Dec 15; 101(12):2057-8; author reply 2059. PMID: 19997112; PMCID: PMC2795433.
      Citations: 1     Fields:    Translation:Humans
    280. Lifshitz DA, Shikanov SA, Deklaj T, Katz MH, Zorn KC, Eggener SE, Shalhav AL. Laparoscopic partial nephrectomy: a single-center evolving experience. Urology. 2010 Feb; 75(2):282-7. PMID: 19962732.
      Citations: 5     Fields:    Translation:Humans
    281. Large MC, Sheinfeld J, Eggener SE. Retroperitoneal lymph node dissection: reassessment of modified templates. BJU Int. 2009 Nov; 104(9 Pt B):1369-75. PMID: 19840015.
      Citations: 11     Fields:    Translation:Humans
    282. Large MC, Eggener SE. Active surveillance for low-risk localized prostate cancer. Oncology (Williston Park). 2009 Oct; 23(11):974-9. PMID: 19947349.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    283. Zorn KC, Gautam G, Shalhav AL, Clayman RV, Ahlering TE, Albala DM, Lee DI, Sundaram CP, Matin SF, Castle EP, Winfield HN, Gettman MT, Lee BR, Thomas R, Patel VR, Leveillee RJ, Wong C, Badlani GH, Rha KH, Eggener SE, Wiklund P, Mottrie A, Atug F, Kural AR, Joseph JV, Members of the Society of Urologic Robotic Surgeons. Training, credentialing, proctoring and medicolegal risks of robotic urological surgery: recommendations of the society of urologic robotic surgeons. J Urol. 2009 Sep; 182(3):1126-32. PMID: 19625032.
      Citations: 52     Fields:    Translation:Humans
    284. Lifshitz DA, Shikanov S, Jeldres C, Deklaj T, Karakiewicz PI, Zorn KC, Eggener SE, Shalhav AL. Laparoscopic partial nephrectomy: predictors of prolonged warm ischemia. J Urol. 2009 Sep; 182(3):860-5. PMID: 19616257.
      Citations: 5     Fields:    Translation:Humans
    285. Alur M, Nguyen MM, Eggener SE, Jiang F, Dadras SS, Stern J, Kimm S, Roehl K, Kozlowski J, Pins M, Michalak M, Dhir R, Wang Z. Suppressive roles of calreticulin in prostate cancer growth and metastasis. Am J Pathol. 2009 Aug; 175(2):882-90. PMID: 19608864; PMCID: PMC2716982.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    286. Shikanov S, Wille M, Large M, Lifshitz DA, Zorn KC, Shalhav AL, Eggener SE. Knotless closure of the collecting system and renal parenchyma with a novel barbed suture during laparoscopic porcine partial nephrectomy. J Endourol. 2009 Jul; 23(7):1157-60. PMID: 19530906.
      Citations: 12     Fields:    Translation:Animals
    287. Eggener SE, Raman JD. Re: Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. S. Baltaci, E. Suer, A. H. Haliloglu, M. I. Gokce, A. H. Elhan and Y. Beduk. J Urol 2009; 181: 128-132. J Urol. 2009 Jul; 182(1):396-7. PMID: 19467675.
      Citations:    Fields:    Translation:Humans
    288. Shikanov S, Song J, Royce C, Al-Ahmadie H, Zorn K, Steinberg G, Zagaja G, Shalhav A, Eggener S. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence. J Urol. 2009 Jul; 182(1):139-44. PMID: 19450829.
      Citations: 23     Fields:    Translation:Humans
    289. Eggener SE. Editorial comment on: Perioperative morbidity of laparoscopic cryoablation of small renal masses with ultrathin probes: a European multicentre experience. Eur Urol. 2009 Aug; 56(2):361-2. PMID: 19467770.
      Citations:    Fields:    Translation:Humans
    290. Jayram G, Eggener SE. Patient selection for focal therapy of localized prostate cancer. Curr Opin Urol. 2009 May; 19(3):268-73. PMID: 19342957.
      Citations: 7     Fields:    Translation:Humans
    291. Katz MH, Eggener SE. The evolution, controversies, and potential pitfalls of modified retroperitoneal lymph node dissection templates. World J Urol. 2009 Aug; 27(4):477-83. PMID: 19363613.
      Citations: 4     Fields:    Translation:Humans
    292. Eggener S. Editorial comment on: Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol. 2010 Mar; 57(3):472. PMID: 19359087.
      Citations: 1     Fields:    Translation:Humans
    293. Eggener SE. The clinical diversity of postchemotherapy germ cell teratoma. Cancer. 2009 Mar 15; 115(6):1138-41. PMID: 19165804.
      Citations:    Fields:    Translation:Humans
    294. Eggener SE, Mueller A, Berglund RK, Ayyathurai R, Soloway C, Soloway MS, Abouassaly R, Klein EA, Jones SJ, Zappavigna C, Goldenberg L, Scardino PT, Eastham JA, Guillonneau B. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol. 2009 Apr; 181(4):1635-41; discussion 1641. PMID: 19233410; PMCID: PMC4237227.
      Citations: 26     Fields:    Translation:HumansPHPublic Health
    295. Orvieto M, Eggener S. Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol. 2009 May; 55(5):1073-4. PMID: 19200640.
      Citations:    Fields:    Translation:HumansPHPublic Health
    296. Jayram G, Msezane LE, Angelos P, Eggener SE. Robotic-assisted partial cystectomy for recurrent extra-adrenal pheochromocytoma. J Robot Surg. 2009 Mar; 3(1):41-3. PMID: 27628452.
      Citations:    Fields:    
    297. Kundu SD, Eggener SE. Retroperitoneal lymph nodes in transitional cell carcinoma of the kidney and ureter. Adv Urol. 2009; 181927. PMID: 19190765; PMCID: PMC2630418.
      Citations: 2     
    298. Reynolds WS, Eggener SE. Editorial comment on: Preservation of lateral prostatic fascia is associated with urine continence after robotic-assisted prostatectomy. Eur Urol. 2009 Apr; 55(4):900-1. PMID: 19171420.
      Citations:    Fields:    Translation:Humans
    299. Eggener SE, Vickers AJ, Serio AM, Donovan MJ, Khan FM, Bayer-Zubek V, Verbel D, Cordon-Cardo C, Reuter VE, Bianco FJ, Scardino PT. Comparison of models to predict clinical failure after radical prostatectomy. Cancer. 2009 Jan 15; 115(2):303-10. PMID: 19025977; PMCID: PMC2740715.
      Citations: 8     Fields:    Translation:Humans
    300. Eggener SE. Editorial comment on: Reducing laparoscopic radical prostatectomy false-positive margin rates using cyanoacrylate tissue glue. Eur Urol. 2009 Oct; 56(4):658. PMID: 19091455.
      Citations:    Fields:    Translation:Animals
    301. Wiltz AL, Shikanov S, Eggener SE, Katz MH, Thong AE, Steinberg GD, Shalhav AL, Zagaja GP, Zorn KC. Robotic radical prostatectomy in overweight and obese patients: oncological and validated-functional outcomes. Urology. 2009 Feb; 73(2):316-22. PMID: 18952266.
      Citations: 54     Fields:    Translation:Humans
    302. Sharp DS, Carver BS, Eggener SE, Kondagunta GV, Motzer RJ, Bosl GJ, Sheinfeld J. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol. 2008 Dec 01; 26(34):5524-9. PMID: 18936477; PMCID: PMC2651099.
      Citations: 35     Fields:    Translation:Humans
    303. Thong AE, Shikanov S, Katz MH, Gofrit ON, Eggener S, Zagaja GP, Shalhav AL, Zorn KC. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes? J Urol. 2008 Dec; 180(6):2436-40. PMID: 18930486.
      Citations: 11     Fields:    Translation:Humans
    304. Eggener SE, Coleman JA. Focal treatment of prostate cancer with vascular-targeted photodynamic therapy. ScientificWorldJournal. 2008 Oct 03; 8:963-73. PMID: 18836668; PMCID: PMC2692990.
      Citations: 10     Fields:    Translation:HumansAnimals
    305. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol. 2008 Nov; 180(5):1964-7; discussion 1967-8. PMID: 18801515; PMCID: PMC2919316.
      Citations: 92     Fields:    Translation:Humans
    306. Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol. 2008 Sep; 180(3):873-8; discussion 878. PMID: 18635225; PMCID: PMC2570431.
      Citations: 45     Fields:    Translation:Humans
    307. Eggener S. Editorial comment on: Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels. Eur Urol. 2009 Mar; 55(3):616. PMID: 18639973.
      Citations:    Fields:    Translation:Humans
    308. Russo P, Jang TL, Pettus JA, Huang WC, Eggener SE, O'Brien MF, Karellas ME, Karanikolas NT, Kagiwada MA. Survival rates after resection for localized kidney cancer: 1989 to 2004. Cancer. 2008 Jul 01; 113(1):84-96. PMID: 18470927; PMCID: PMC3985136.
      Citations: 38     Fields:    Translation:Humans
    309. Yossepowitch O, Thompson RH, Leibovich BC, Eggener SE, Pettus JA, Kwon ED, Herr HW, Blute ML, Russo P. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol. 2008 Jun; 179(6):2158-63. PMID: 18423758; PMCID: PMC2704565.
      Citations: 61     Fields:    Translation:Humans
    310. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Tsodikov A, Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA, Bjartell AS, Chinnaiyan AM, Andrén O, Stenman UH. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell. 2008 Jun; 13(6):519-28. PMID: 18538735; PMCID: PMC2732022.
      Citations: 144     Fields:    Translation:HumansCells
    311. Jang TL, Pettus JA, Huang WC, Eggener SE, O'Brien MF, Karellas ME, Kagiwada MA, Russo P. Survival rates after resection for localized kidney cancer: 1989 - 2004. J Clin Oncol. 2008 May 20; 26(15_suppl):5115. PMID: 27948049.
      Citations:    
    312. Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, Catalona WJ. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology. 2008 Jun; 71(6):1016-9. PMID: 18358515.
      Citations: 12     Fields:    Translation:Humans
    313. Eggener SE, Guillonneau B. Laparoscopic radical prostatectomy: ten years later, time for evidence-based foundation. Eur Urol. 2008 Jul; 54(1):4-7. PMID: 18339477.
      Citations: 4     Fields:    Translation:Humans
    314. Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA, Ohori M, Kuroiwa K, Rossignol M, Abenhaim L, International Task Force on Prostate Cancer and the Focal Lesion Paradigm. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007 Dec; 178(6):2260-7. PMID: 17936815.
      Citations: 86     Fields:    Translation:Humans
    315. Yossepowitch O, Eggener SE, Serio AM, Carver BS, Bianco FJ, Scardino PT, Eastham JA. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008 May; 53(5):950-9. PMID: 17950521; PMCID: PMC2637146.
      Citations: 55     Fields:    Translation:Humans
    316. Carver BS, Shayegan B, Eggener S, Stasi J, Motzer RJ, Bosl GJ, Sheinfeld J. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2007 Oct 01; 25(28):4365-9. PMID: 17906201.
      Citations: 44     Fields:    Translation:Humans
    317. Eggener S. Editorial comment on: Methods of calculating prostate-specific antigen velocity. Eur Urol. 2007 Oct; 52(4):1050-1. PMID: 17933029.
      Citations:    Fields:    Translation:Humans
    318. Oram SW, Ai J, Pagani GM, Hitchens MR, Stern JA, Eggener S, Pins M, Xiao W, Cai X, Haleem R, Jiang F, Pochapsky TC, Hedstrom L, Wang Z. Expression and function of the human androgen-responsive gene ADI1 in prostate cancer. Neoplasia. 2007 Aug; 9(8):643-51. PMID: 17786183; PMCID: PMC1950434.
      Citations: 26     Fields:    Translation:HumansCells
    319. Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, Fine SW, Udby L, Gerald WL, Vickers AJ, Lilja H, Reuter VE, Scardino PT. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res. 2007 Jul 15; 13(14):4130-8. PMID: 17634540; PMCID: PMC2660867.
      Citations: 40     Fields:    Translation:Humans
    320. Yossepowitch O, Eggener SE, Bianco FJ, Carver BS, Serio A, Scardino PT, Eastham JA. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol. 2007 Aug; 178(2):493-9; discussion 499. PMID: 17561152.
      Citations: 77     Fields:    Translation:Humans
    321. Eggener SE, Yossepowitch O, Serio AM, Vickers AJ, Scardino PT, Eastham JA. Radical prostatectomy shortly after prostate biopsy does not affect operative difficulty or efficacy. Urology. 2007 Jun; 69(6):1128-33. PMID: 17572200.
      Citations: 13     Fields:    Translation:Humans
    322. Eggener SE, Carver BS, Sharp DS, Motzer RJ, Bosl GJ, Sheinfeld J. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol. 2007 Mar; 177(3):937-42; discussion 942-3. PMID: 17296380.
      Citations: 29     Fields:    Translation:Humans
    323. Eggener SE, Carver BS, Loeb S, Kondagunta GV, Bosl GJ, Sheinfeld J. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer. 2007 Feb 01; 109(3):528-35. PMID: 17177200.
      Citations: 19     Fields:    Translation:Humans
    324. Pettus JA, Eggener SE, Shabsigh A, Yanke B, Snyder ME, Serio A, Vickers A, Russo P, Donat SM. Perioperative clinical thromboembolic events after radical or partial nephrectomy. Urology. 2006 Nov; 68(5):988-92. PMID: 17113889.
      Citations: 8     Fields:    Translation:Humans
    325. Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JA, Catalona WJ. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. Urol Oncol. 2006 Nov-Dec; 24(6):465-71. PMID: 17138126.
      Citations: 6     Fields:    Translation:HumansPHPublic Health
    326. Yossepowitch O, Bianco FJ, Eggener SE, Eastham JA, Scher HI, Scardino PT. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol. 2007 Apr; 51(4):940-7; discussion 947-8. PMID: 17125912; PMCID: PMC2646889.
      Citations: 14     Fields:    Translation:Humans
    327. Yossepowitch O, Eggener SE, Serio A, Huang WC, Snyder ME, Vickers AJ, Russo P. Temporary renal ischemia during nephron sparing surgery is associated with short-term but not long-term impairment in renal function. J Urol. 2006 Oct; 176(4 Pt 1):1339-43; discussion 1343. PMID: 16952626.
      Citations: 18     Fields:    Translation:Humans
    328. Eggener SE, Roehl KA, Yossepowitch O, Catalona WJ. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. J Urol. 2006 Oct; 176(4 Pt 1):1399-403. PMID: 16952643.
      Citations: 1     Fields:    Translation:Humans
    329. Yossepowitch O, Eggener SE, Bochner BH, Donat SM, Herr HW, Dalbagni G. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. J Urol. 2006 Aug; 176(2):482-5. PMID: 16813873.
      Citations: 16     Fields:    Translation:Humans
    330. Eggener S, Herr H. NMP22 and surveillance for recurrent bladder cancer. JAMA. 2006 Jul 05; 296(1):45; author reply 45-6. PMID: 16820545.
      Citations: 1     Fields:    Translation:Humans
    331. Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006 Jul 01; 24(19):3101-6. PMID: 16809736.
      Citations: 107     Fields:    Translation:Humans
    332. Eggener SE, Stern JA, Jain PM, Oram S, Ai J, Cai X, Roehl KA, Wang Z. Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate. 2006 Apr 01; 66(5):495-502. PMID: 16372330.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    333. Nadler RB, Loeb S, Roehl KA, Antenor JA, Eggener S, Catalona WJ. Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol. 2005 Dec; 174(6):2154-7, discussion 2157. PMID: 16280754.
      Citations: 6     Fields:    Translation:Humans
    334. Eggener SE, Roehl KA, Catalona WJ. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy. J Urol. 2005 Aug; 174(2):500-4. PMID: 16006880.
      Citations: 11     Fields:    Translation:Humans
    335. Antenor JA, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJ. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology. 2005 Jul; 66(1):156-60. PMID: 15992903.
      Citations: 15     Fields:    Translation:Humans
    336. Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res. 2005 Jul 01; 11(13):4905-11. PMID: 16000589.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    337. Eggener SE, Lotan Y, Cheng EY. Magnetic resonance angiography for the nonpalpable testis: a cost and cancer risk analysis. J Urol. 2005 May; 173(5):1745-9; discussion 1749-50. PMID: 15821574.
      Citations: 2     Fields:    Translation:Humans
    338. Eggener SE, Roehl KA, Smith ND, Antenor JA, Han M, Catalona WJ. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy. J Urol. 2005 Apr; 173(4):1150-5. PMID: 15758725.
      Citations: 9     Fields:    Translation:Humans
    339. Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol. 2004 Dec; 172(6 Pt 1):2227-31. PMID: 15538237.
      Citations: 114     Fields:    Translation:Humans
    340. Thaxton CS, Eggener SE, Schaeffer AJ. Plasma cell infiltration of the urinary bladder. Urology. 2004 Jul; 64(1):156-7. PMID: 15245959.
      Citations: 1     Fields:    Translation:HumansCells
    341. Eggener SE, Abrahams A, Keeler TC. Granulocytic sarcoma of the testis. Urology. 2004 Mar; 63(3):584-5. PMID: 15028471.
      Citations: 7     Fields:    Translation:HumansCells
    342. Eggener SE, Dalton DP. Bilateral pulmonary artery tumour emboli from renal carcinoma. Lancet Oncol. 2004 Mar; 5(3):173. PMID: 15003200.
      Citations:    Fields:    Translation:Humans
    343. Eggener S, Kim SC, User HM, Pazona J, Nadler RB. Urolithiasis associated with topiramate. Int Braz J Urol. 2004 Jan-Feb; 30(1):29-30; discussion 30-1. PMID: 15707510.
      Citations:    Fields:    Translation:Humans
    344. Eggener SE, Rubenstein JN, Smith ND, Nadler RB, Kontak J, Flanigan RC, Waters WB, Picken M, Campbell SC, Rubenstein JR. Renal tumors in young adults. J Urol. 2004 Jan; 171(1):106-10. PMID: 14665855.
      Citations: 22     Fields:    Translation:Humans
    345. Eggener SE, Stern JA, Smith ND, Gonzalez CM. Penile refracture: case report. J Trauma. 2003 Oct; 55(4):793-4. PMID: 14566143.
      Citations:    Fields:    Translation:Humans
    346. Eggener SE, Hua V, Schaeffer AJ, Smith ND. A noninfectious source of renal gas: embolization. J Urol. 2003 Sep; 170(3):913. PMID: 12913729.
      Citations:    Fields:    Translation:Humans
    347. Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol. 2003 Apr; 169(4):1219-28. PMID: 12629332.
      Citations: 36     Fields:    Translation:HumansAnimals
    348. Nadler RB, Rubenstein JN, Eggener SE, Loor MM, Smith ND. The etiology of urolithiasis in HIV infected patients. J Urol. 2003 Feb; 169(2):475-7. PMID: 12544290.
      Citations: 11     Fields:    Translation:Humans
    349. Rodriguez HE, Eggener SE, Podbielski FJ, Brown AM, Amble S, Clark ET, Smith ND. Occlusion of an intraluminal endovascular stent graft after treatment of a ureteral-iliac artery fistula. Urology. 2002 Nov; 60(5):912. PMID: 12429336.
      Citations: 4     Fields:    Translation:Humans
    350. Raviv S, Eggener SE, Williams DH, Garnett JE, Pins MR, Smith ND. Long-term survival after "drop metastases" of renal cell carcinoma to the bladder. Urology. 2002 Oct; 60(4):697. PMID: 12385938.
      Citations: 10     Fields:    Translation:Humans
    351. Rubenstein JN, Hairston JC, Eggener SE, Gonzalez CM. Irritative voiding symptoms and microscopic hematuria caused by intraperitoneal calcified fat necrosis. Urology. 2002 Mar; 59(3):444. PMID: 11880093.
      Citations: 1     Fields:    Translation:Humans
    352. Reiher F, Ozer O, Pins M, Jovanovic BD, Eggener S, Campbell SC. p53 and microvessel density in primary resection specimens of superficial bladder cancer. J Urol. 2002 Mar; 167(3):1469-74. PMID: 11832772.
      Citations: 5     Fields:    Translation:Humans
    353. Brooks JD, Eggener SE, Chao WM. Anatomy of the rectourethralis muscle. Eur Urol. 2002 Jan; 41(1):94-100. PMID: 11999473.
      Citations: 12     Fields:    Translation:Humans
    354. Rubenstein JN, Eggener SE, Pins MR, Rosner K, Chugh S, Campbell SC. Juxtaglomerular apparatus tumor: a rare, surgically correctable cause of hypertension. Rev Urol. 2002; 4(4):192-5. PMID: 16985680; PMCID: PMC1475994.
      Citations: 6     
    355. Eggener SE, Hairston J, Rubenstein JN, Gonzalez CM. Bladder lipoma. J Urol. 2001 Oct; 166(4):1395. PMID: 11547089.
      Citations: 2     Fields:    Translation:Humans
    356. Eggener S. The power of the pen: medical journalism and public awareness. JAMA. 1998 May 06; 279(17):1400. PMID: 9582053.
      Citations: 4     Fields:    Translation:Humans
    357. Dietz NM, Rivera JM, Eggener SE, Fix RT, Warner DO, Joyner MJ. Nitric oxide contributes to the rise in forearm blood flow during mental stress in humans. J Physiol. 1994 Oct 15; 480 ( Pt 2):361-8. PMID: 7869251; PMCID: PMC1155852.
      Citations: 83     Fields:    Translation:HumansCTClinical Trials
    Eggener's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (609)
    Explore
    _
    Co-Authors (66)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _